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 In the developing vertebrate embryo, multipotent cells of the paraxial 
mesoderm form epithelial spheres called somites that physically define the 
segmentation pattern of the embryo.  MyoD is transcribed in the myogenic 
precursor cells of the developing somite and is essential for proper hypaxial 
muscle formation.  Whether MyoD is a determination factor or downstream 
member of the myogenic program had yet to be shown and the cis-transcriptional 
control of this important gene was incompletely defined.   
By permanently labeling cells that have transcribed the MyoD locus in 
MyoD-/-/Myf-5-/- embryos, where myogenesis does not occur, the determination 
state of presumptive myoblasts has been revealed.  Previous studies used a 
temporary cell labeling system and suggested that in MyoD-/-/Myf-5-/- embryos, 
cells of the MyoD lineage apoptose and do not contribute to other cell types.  
This suggests that the MyoD lineage is committed to myogenesis before 
myoblasts form.  In the results presented herein, cells that have activated the 
MyoD locus persist until birth and contribute to bone, brown adipose tissue and 
connective tissue demonstrating the multipotent nature of premyogenic cells prior 
to MyoD activation. 
  The genetic regulatory elements controlling MyoD expression were 
thought to be the core enhancer (CE) and distal regulatory region (DRR), where 
the CE initiates MyoD expression and the DRR maintains it.  Deletion of either 
the CE or DRR from the mouse genome resulted in only mild phenotypes and 
suggested more complexity in MyoD regulation.  Here, we deleted both the CE 
and DRR to determine if the enhancers have compensatory abilities or if other 
unknown regulatory elements exist.  In situ hybridization for MyoD mRNA in our 
new line of mouse embryos shows that removal of both enhancers does not 
seriously alter the MyoD expression profile.  The phenotypes seen in the 
individual knockout embryos are both present when the CE and DRR are 
removed.  Genomic database analysis implicates the introns of MyoD as the 
uncharacterized enhancers. 
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Chapter 1: Introduction  
 
Skeletal myogenesis is vital for motility, and the transcriptional regulation of a 
potent myogenic transcription factor, MyoD, and the determination state of 
embryonic cells poised to enter the myogenic program have yet to be fully 
explained.  This thesis focuses on MyoD in the hopes that basic scientific 
knowledge of its function and regulatory elements can advance the field toward a 
more nuanced understanding of myogenesis.  This introduction will provide 
background knowledge on the genes involved and the process of embryonic 
myogenesis.    
 
  
1.1 Identification of the Myogenic Regulatory Factors: 
 
 Embryologists, and now stem cell biologists, have been interested in 
finding what gene products could convert multipotent progenitor cells to become 
developmentally restricted to a single cell type.  Early insight into the genes 
controlling skeletal muscle formation was gleaned by experiments where 10T1/2 
fibroblasts were converted to differentiated skeletal muscle cells by treatment 
with the DNA demethylating agent 5-azacytidine (Constantinides, 1977).  5-
azacytidine is a cytosine nucleotide analog that can not be methylated and was 
introduced into dividing fibroblasts.   To find what transcripts were responsible for 
the phenotypic change in fibroblasts, subtractive hybridization was performed 
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between the two populations, revealing a cDNA, that when ectopically expressed, 
was capable of converting 10T1/2 fibroblasts, nerve, pigment, fat, and liver cells  
muscle (Davis et al., 1987; Weintraub et al., 1989).  The gene activated due loss 
of methylation and responsible for the fate switches when over expressed was 
named MyoD for ‘myogenic determination gene’. 
Subsequent to the identification of MyoD, three other genes possessing 
the ability to convert non-muscle cells to muscle were identified.   Looking for 
related transcription factors, MyoD cDNA was used as a probe in low stringency 
conditions to fish for transcripts in myogenic cells lines and from mRNA extracted 
from adult rat muscle.   The three genes found were, Myogenin (Olson et al., 
1990; Wright et al., 1989), Myf-5 (Braun et al., 1989), and Mrf4(Braun et al., 
1990; Miner and Wold, 1990).  These four genes are expressed only in skeletal 
muscle or mesodermal precursor cells and encode highly related transcription 
factors containing 95% amino acid homology within a centrally located 70 amino 
acid basic helix-loop-helix (bHLH) domain which is necessary for DNA binding 
and dimerization (Ishibashi et al., 2005; Olson et al., 1990).   
 
1.2 Myogenic Regulatory Factor Function: 
 
Formation of function skeletal muscle occurs via two broad phases, 
determination and differentiation.  Determination occurs when a multipotent 
progenitor becomes committed to the myogenic fate and contributes to the 
proliferative progenitor pool of myoblasts.  During differentiation, myoblasts fuse 
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with each other to form multinucleated myotubes that will eventually become 
muscle fibers.  
Muscle based mobility is essential for life in non-sedentary organisms and 
there would be no muscle fibers without the determination of the myogenic 
lineage and formation of myoblasts.  MyoD, Myf-5, and Mrf4 are the three genes 
currently shown to be involved in myoblast formation.  Absence of the protein 
products from the MyoD, Myf-5, and Mrf4 genes in the developing mouse embryo 
results in new born mice devoid of skeletal muscle (Rudnicki et al., 1993).  
Importantly, not only was mature skeletal muscle absent, but cells expressing 
markers of myoblasts, the single cell proliferative precursors of muscle fibers, 
were absent as well (Kablar et al., 2003).  The original Myf-5 knock out allele, 
Myf-5Neo, unknowingly blocking transcription of Mrf4 during early development 
(Kassar-Duchossoy et al., 2004).  A more recent knock out allele, Myf-5loxP, does 
not affect Mrf4 transcription and paraxial mesoderm cells form myosin heavy 
chain positive muscle cells in the absence of only MyoD and Myf-5.  However, 
Mrf4 is not capable of establishing a robust myogenic population and MyoD-/-
;Myf-5-/- embryos are born largely devoid of skeletal muscle. Removal of either 
MyoD or Myf-5 results in transient defects or delays in myogenesis, and 
ultimately ends with a viable mouse with functional muscle (Braun et al., 1992; 
Rudnicki et al., 1992).  MyoD and Myf-5 may appear to have grossly overlapping 
functions, evidenced by the single and double knock out phenotypes, but they 
have differing genomic targets and specific functions during myogenesis. Real 
time PCR expression data shows that MyoD is much more efficient at activating 
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differentiation genes than Myf-5, while both proteins were shown to activate 
growth phase target genes (Ishibashi et al., 2005).  Also, Myf-5-/- myoblasts 
differentiate prematurely in vitro, at the expense of proliferation, (Montarras et al., 
2000) while MyoD-/- myoblasts divide quickly and differentiate poorly (Sabourin et 
al., 1999).  A more in depth review of MyoD function can be found in the following 
sections. 
Myogenin controls myogenic differentiation due to the fact that in 
Myogenin knock out embryos, there are severe differentiation defects and 
embryos die a birth, while myoblasts and primary myogenesis occurs normally 
(Venuti et al., 1995).  Historically, Mrf4 has been thought to be a differentiation 
factor as Mrf4 null animals have normal muscle determination and differentiation, 
but there is a four fold increase in Myogenin expression, likely a compensation 
mechanism (Braun and Arnold, 1995).  However, as stated above, Mrf4 can play 
a role in myoblast formation.   
 
1.3 MyoD; Structure and Function: 
 
MyoD belongs to a subfamily of bHLH transcription factors involved in 
myogenesis.  The bHLH family of transcription factors falls into two broad 
categories.  One is called Class I, and are broadly expressed in many cell types 
and contain the E protein family.  Class II bHLH factors, that the MRFs are 
members of, expression is restricted in a tissue specific manner.  As mentioned 
previously, forced MyoD expression in differentiated non muscle cells in vitro can 
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be converted to muscle (Weintraub et al., 1989).  For this to happen, genes must 
be silenced, new genes activated, and chromatin remodeled.  MyoD has the 
ability to perform all of these functions and deserves a detailed description of its 
structure, and more broadly the structure of bHLH transcription factors, and the 
signaling pathways involving MyoD to describe its function.     
 
1.3.1 Structure: 
 
MyoD and the other MRFs share two domains with each other and with 
other bHLH (basic helix-loop-helix) transcription factors, the DNA binding and 
dimerization domains.  Variability among these factors lies in the presence, 
absence, or combination of activation domains and repressive domains.   The 
common element  is comprised of approximately 60 amino acids containing the 
DNA binding region (basic) followed by two alpha-helices, separated by a 
variable loop region (HLH) (Ferre-D'Amare et al., 1993).   The HLH domain 
allows for dimerization between two HLH containing factors, either through 
homodimerization, which is uncommon, or through heterodimerization (Kadesch, 
1993).  Once dimerized, the basic regions of the two transcription factors bind 
specific DNA sequences.  During myogenesis, the MRF’s bind E-boxes, whose 
consensus sequence is CANNTG, where N can be any nucleotide.  MyoD has a 
strong, single transcriptional activation domain at the amino terminal end and a 
histine-cystine rich domain containing a tryptophan amino acid necessary for 
interaction with the Pbx/Meis complex, a known transcriptional activator (Okada 
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et al., 2003; Tapscott, 2005).    The strong transactivation domain of MyoD has 
been used in a fusion protein with the DNA binding domain of Oct4 for a 50 fold 
increase in production of induced pluripotent stem cells (iPSCs), partly due to the 
chromatin remodeling ability of MyoD (Hirai et al., 2010).  
 
1.3.2 Function: 
 
MyoD is a master transcription factor that remodels chromatin and recruits 
activating transcriptional complexes to the loci of many genes involved in all 
aspects of myogenesis.  MyoD does not perform all of its functions at once, 
rather there is a temporal specificity to its actions, with some genes influenced 
immediately, and others influenced within days of initiation of expression (Lin et 
al., 1994; Zhao et al., 2002).  MyoD has been shown to directly bind both early 
and late genomic targets via CHiP data in a fibroblast cell line containing an 
estrogen induced MyoD allele (Bergstrom et al., 2002).  The proposed cause of 
this phenomenon is a feed-forward mechanism, where early targets of MyoD are 
needed to cooperate with MyoD to activate the next temporal level of genes 
(Penn et al., 2004).   Acetylation of the MyoD protein has also been shown to 
affect target gene selection (Di Padova et al., 2007). 
 The simplified description of MyoD function is that it heterodimerizes with 
the structurally similar, but broadly expressed, E-proteins through their shared 
HLH domains.  Specifically, MyoD is shown to heterodimerize with E12 and E47 
to activate myogenic genes, and this activation ability is at least partly governed 
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by the MAP kinase p38 (Watada et al., 1995).  p38 phosphorylates E47 at serine 
140, and this modification is essential for association with MyoD (Lluis et al., 
2005).  Then, through a combination of the lone activation domain of MyoD and 
the variable activation/repression domains of the E-proteins, target genes are 
activated or repressed.  Strangely, the target DNA sequence of MyoD is short, 
(CANNTG) and occurs frequently through out the mammalian genome.  A large 
amount of regulation via protein interactions are therefore required to obtain 
target gene and temporal specificity.  Specificity is achieved either by tandem E 
boxes, or a combination of E boxes and binding sites for cooperative factors that 
directly interact with the activation domain of MyoD, such as Mef2, Pbx, Meis, 
and Sp1 (Knoepfler et al., 1999; Sartorelli et al., 1997; Sartorelli et al., 1990)     
(Tapscott, 2005). 
 An essential family of transcription factors needed for activation of 
essentially all myogenic genetic loci, is the MEF2 (myocyte enhancement factor) 
family.  In mice, there are four members of the MEF2 family, and they are 
required for the differentiation, but not specification of the myogenic lineage 
(Black and Olson, 1998).  Although MyoD and the MEF2 family bind different 
consensus DNA sequences, both sequences are found at almost every skeletal 
muscle genes promoter region, and efficient transcription of those genes only 
occurs when both factors are bound (Dodou et al., 2003; Li and Capetanaki, 
1994; Malik et al., 1995).   
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1.3.2.1 Chromatin Modification and Remodeling: 
 
Part of the temporal specificity in MyoD mediated myogenesis is due to 
binding sites being hidden via inaccessible chromatin states.  Many of the E-box 
targets of MyoD and the other MRFs, are hidden by unfavorable chromatin at 
time specific loci, or loci initially targeted at the onset of myogenesis.   MyoD has 
the ability to alter the epigenome of myogenic cells, by directly interacting with 
the histone acetyltransferases (HATs), p300 and CBP (Bannister and Kouzarides, 
1996; Ogryzko et al., 1996).  Addition of acetyl groups to histone tails negates 
their positive charge resulting in the weakening of their interaction with the 
negatively charged DNA, allowing access to the DNA sequence.  The 
MyoD/p300/CBP complex can recruit another HAT, p300/CBP-associated factor 
(PCAF), resulting in a complex with two differing acetyltransferase abilities and 
specificities (Puri et al., 1997; Sartorelli et al., 1997).  p300 acetylates histone 
proteins, weakening the protein-DNA interaction, allowing that region of DNA to 
be accessible to transcription factors.  PCAF acetylates the MyoD protein at two 
lysine residues just outside of the DNA binding domain, increasing the 
transcriptional activation ability of MyoD (Polesskaya et al., 2000) (Dilworth et al., 
2004).   
Besides associating with histone modifying proteins, MyoD also recruits 
protein complexes known to remodel chromatin.  The large ATP-dependent 
SWI/SNF complex, actively moves histones or switches out nucleosome histone 
subunits to facilitate transcription of previously silent local genes (de la Serna et 
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al., 2005; Hirschhorn et al., 1992).  The SWI/SNF complex directly interacts with 
MyoD via the BAF60c subunit (Forcales, 2012). 
 
1.3.2.2 Association with RNA Helicases: 
 
 MyoD has been shown to interact with two different RNA helicases, p68 
and p72.   Generally, RNA helicases are enzymes that alter RNA structure and 
are therefore involved in all aspects of RNA structure modification during 
transcription, splicing, and translation (Abdelhaleem, 2004).   RNA helicases 
mediate conversion between single stranded RNA and double stranded RNA, 
and also affects the affinity of RNA for specific proteins.  For a comprehensive 
review, see (Jarmoskaite and Russell, 2011; Pan and Russell, 2010).  The role of 
RNA helicases involved in controlling cell determination or differentiation comes 
from work showing a direct interaction between MyoD and p68 and p72.  When 
p68 and p72 are knocked down in HeLa cells or the immortal myoblast line, 
C2C12, myogenic differentiation is severely diminished, such that multinucleated 
myotubes never from in vitro and the cells fail to express myosin heavy chain, a 
hallmark of differentiating skeletal muscle.  The proposed mechanism for the 
inhibition of myogenic differentiation is through the lack of effective transcriptional 
initiation complex formation at the promoters of myogenic genes, and also 
through a failure of chromatin remodeling (Fuller-Pace and Ali, 2008). 
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1.3.2.3 Transcriptional Repression by MyoD: 
 
 As a pioneer transcription factor, MyoD must remodel chromatin to access 
target genes that are physically hidden, and then activate transcription of those 
genes.  By virtue of MyoD’s ability to convert non-muscle cell types to the 
myogenic lineage, it would be logical to assume that MyoD can repress genes 
expressed in the cell type before myogenic conversion.   
microRNAs (miRNA) are short, approximately 20 nucleotides in length, 
single stranded RNAs that negatively impact gene expression by directing 
degradation of specific mRNAs or inhibiting translation (Luo et al., 2013).  Three 
miRNAs, miR-1, 133, and 206 are all restricted to muscle cells and may be 
controlled by the MRFs. MyoD has been shown to directly activate the 
transcription of mIR-206, that suppress translation of transcripts expressed in 
fibroblasts.  Two genes expressed in fibroblasts, utrophin (Utrn) and follistatin-
like 1 (Fstl1) have their mRNA reduced after the onset of MyoD expression due 
to the fact that MyoD directly binds an E box near the genomic locus of miR-206.  
The miR-206 locus is next to a gene activated by MyoD, AK132452, and mIR-
206 may be a result of processing of that gene.  miR-206 then complementary 
base pairs the 3’ UTR of  Fstl1 transcripts, targeting them for destruction 
(Rosenberg et al., 2006).  It is also suggested that MyoD activates transcription 
of miR-133 and miR-1.  These miRNAs target the destruction of a histone 
deacetylase, HDAC4, a transcriptional repressor, and serum response factor 
(SRF), an anti-mitotic protein (Chen et al., 2006).    The action of MyoD via 
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miRNAs promotes cell proliferation and gene expression at certain loci, while 
repressing transcripts characteristic of non-myogenic lineages. 
Another method of transcriptional repression via MyoD is through histone 
deacetylase complexes (HDACs).  MyoD recruits HDACs to genetic loci where 
histones will be modified such that the genes close by will be repressed (Puri et 
al., 2001).  This phenomenon may be part of the temporal regulation of MyoD 
target genes, as these repressive complexes are also seen at the Myogenin 
promoter, a locus known to be activated by MyoD.  While a myoblast is 
proliferating, some MyoD target genes will be activated at a later time, and need 
to be temporarily repressed to avoid premature differentiation, and association 
with HDACs is one pathway to achieve this effect. 
 
1.4 Embryonic Myogenesis: 
 
1.4.1 Somitogenesis: 
 
During early embryogenesis, the neural tube and notochord lie at the 
center of the embryo and define the anterior-posterior axis by their action as 
signaling centers that induce surrounding tissues to adopt certain fates through 
secreted factors and direct cell-cell interactions.  On both sides of the neural tube 
resides the paraxial mesoderm, a mesenchyme of multipotent cells that 
eventually give rise to skeletal muscle, the axial skeleton, and the dermis of the 
trunk.   Somites are epithelial spheres formed from segmentation of the paraxial 
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mesoderm with a fixed periodicity starting at the anterior region of the embryo 
and steadily progressing toward the posterior. Somites form with a fixed 
periodicity governed by a ‘molecular clock’.   Many factors control the periodicity 
of somite formation such as FGF8 (fibroblast growth factor 8) and Wnt3a 
(Dubrulle et al., 2001) (Aulehla et al., 2003).  Cycling expression of Notch family 
members and their receptor components play an integral role in the 
segmentation clock in all vertebrates (Gridley, 2006).   The morphological 
boundary between each somite in mice is controlled by two bHLH transcription 
factors, MesP2, regulated by Notch, and Paraxis (Sosic et al., 1997).  If either of 
these genes is removed from the mouse genome, the paraxial mesoderm fails to 
undergo the mesenchymal to epithelial transition, and somites fail to form.  These 
mutations are lethal at birth due to fused vertebra and disorganized axial muscle.  
Interestingly, the cell types found in a normal proper somite still form, but 
segmentation and patterning are lethally incorrect.   MesP2 directly activates 
Eph4A, a gene involved in cell-cell interaction, specifically cell-cell repulsion, an 
action vital to somite formation (Burgess et al., 1996; Saga et al., 1997; 
Takahashi et al., 2005).  The initial somite is plastic in regards to what somitic 
lineage it will become, as shown in somite rotation experiments (Dockter and 
Ordahl, 2000).   Within a few hours of somite formation, the epithelial sphere 
begins to change as lineage specification occurs.  The dorsal portion of the 
somite maintains its epithelial nature and forms the dermomyotome, while the 
ventral portion form the mesenchymal sclerotome (discussed below). 
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  The dermomyotome is a transient structure, where cells on the end of the 
epithelial sheet delaminate, or lose their epithelial shape to become 
mesenchymal.  Factors secreted from the overlying ectoderm (Wnts1 and 7A) 
(Tajbakhsh et al., 1998) induce myogenesis in dermomyotomal cells, while the 
lateral plate mesoderm inhibits myogenesis in other cells types via BMP4.  The 
premyogenic cells activate MyoD or Myf-5 and migrate immediately medially to 
populate the area under the dermomyotome, forming the myotome, the first 
skeletal muscle of the embryo (Kalcheim et al., 1999). Subsequently, the 
dermomyotome provides progenitor cells for all trunk and limb musculature.  The 
dermomyotome also produces trunk dermis, and limb endothelial cells (Kardon et 
al., 2002a).  The ventro-medial portion of the somite loses its epithelial nature to 
return to a mesenchyme and becomes the sclerotome, and gives rise to the ribs, 
vertebra, and tendons of the axial skeleton(Wilting et al., 1994).  This cell 
structure conversion is controlled by Sonic Hedgehog (Shh), produced by the 
notochord and floorplate of the neural tube by activating Pax1 in the future 
sclerotome, and along with BMP4, the early formation of the axial skeleton 
begins (Murtaugh et al., 1999). 
 
1.4.2 Myogenic Lineages: 
 
All skeletal muscle in the embryo is not formed through an identical 
pathway.  At different anatomical locations in the body, there are differing 
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environments and embryonic signaling centers regulating MRF expression.  The 
three major sites of skeletal muscle determination are the head, limbs and trunk.   
 
1.4.2.1 Craniofacial Myogenesis: 
 
Skeletal muscle of the head does not originate from somites, but from 
unsegmented prechordal mesoderm located cranially to the first somite and from 
the branchial arches.  The branchial arches, a subset of the craniofacial muscle 
population, are embryonic structures evolved from gill structures in fish, and in 
mammals their derivatives still control feeding and breathing.  MyoD is 
transcriptionally regulated differently in head muscles than in the body.  In the 
body, Myf-5 and Pax3 are genetically upstream of MyoD because in their 
absence, MyoD is not expressed.  In these mutant embryos, MyoD expression 
occurs normally in the head and myogenesis occurs (Tajbakhsh et al., 1997).  In 
the absence of Myf-5 and MyoD, some trunk musculature forms due to Mrf4 
expression, but Mrf4 is not expressed in the head and as a result, no myofibers 
form in the head, demonstrating the differing upstream activators in the two 
populations (Kassar-Duchossoy et al., 2004).   
MyoR and Capsulin are bHLH factors related to the four major myogenic 
bHLH transcription factors, and are expressed in migratory myogenic precursors 
that travel from the unsegmented paraxial mesoderm to the branchial arches. 
(Hacker and Guthrie, 1998; Noden, 1983; Noden et al., 1999) Specific head 
muscles controlling mastication are missing in embryos missing functional MyoR 
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(Msc or Musculin) and Capsulin (TCF21 or epicadian) genes.   MyoD and Myf-5 
are not turned on in the first branchial arch in the absence MyoR and Capsulin 
(Lu et al., 2002).  Tbx1 and Pitx2 also regulate myogenesis in the branchial 
arches due to resulting muscle defects when either gene is missing (Dong et al., 
2006; Kelly et al., 2004).  These phenotypes are restricted to the head, 
supporting the fact that head and body myogenesis differ significantly.   
 
1.4.2.2  Epaxial Myogenesis: 
 
Muscle of the trunk and limbs arise from the dermomyotome of the 
maturing somite and are broken down into two categories; epaxial and hypaxial 
musculature.  Epaxial muscle progenitors originate from the dorso-medial aspect 
of the dermomyotome and form deep back muscles (Ordahl and Le Douarin, 
1992), while hypaxial muscle precursors delaminate from the ventro-lateral 
portion of the dermomyotome and give rise to ventral body wall muscle, and at 
limb level somites, to the limb musculature(Christ B, 1977). 
Formation of the early musculature in the embryo is a multiphase process.  
Initially, a small group of cells at the dorso-medial lip of the dermomyotome, 
closest to the neural tube, lose their epithelial nature, activate Myf-5 via Wnt1 
and Shh (Cossu et al., 1996a), and migrate ventrally to create the primary 
myotome.  Timely myotome formation is dependent on Myf-5,as there is a one 
day delay in myotome formation in Myf-5 null embryos(Arnold and Braun, 1996; 
Braun et al., 1992).  Pax3 is initially expressed throughout the somite, but its 
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expression becomes limited to the dermomyotome.  Ectopic Pax3 expression 
can activate MyoD and Myf-5 in mesoderm and neural tube explants (Daston et 
al., 1996; Williams and Ordahl, 1994).  These early myotomal cells form the 
pioneer fibers that become the scaffold for the new myogenic cells which begin to 
arrive from all sides of the dermomyotome (Kahane et al., 2007).  Ultimately, the 
central dermomyotome breaks down and Pax3/7 expressing cells enter the 
myotome directly.     
 
1.4.2.3 Hypaxial Myogenesis: 
 
The hypaxial lineage comprises abdominal wall muscles, the diaphragm, 
and limb musculature (Kablar and Rudnicki, 2000).  MyoD is activated in the 
hypaxial domain of the dermomyotome via Wnt7a (Cossu et al., 1996b).  MyoD 
controls timely formation of hypaxial muscle lineages, as MyoD-/- embryos have a 
one day delay in hypaxial myogenesis (Kablar et al., 2003).  At inter limb levels, 
the hypaxial myotome matures into intercostal and abdominal wall muscle.  At 
limb levels, a different phenomenon occurs where single cells are released from 
the lateral portion of the dermomyotome, do not express any of the MRFs, and 
migrate directly to the limb buds where they will activate the MRFs, proliferate 
and eventually differentiate. 
Many genes are known to control the delamination and migration of these 
cells.  Pax3 is arguably the most important gene as mutant mice lacking this 
gene have no limb muscle, while trunk myogenesis is not affected (Bober et al., 
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1994).  Pax3 is positively regulated by Dach2, the vertebrate analog of the 
Drosphila gene dachshund which is involved in the eye formation pathway 
(Kardon et al., 2002b).  Two members of a six member gene family are also 
involved in proper migration of limb myogenic precursors are Six1 and Six4 
(Grifone et al., 2005).   These two genes are genetically upstream of Pax3, as 
are Eya1 and Eya2 (Grifone et al., 2007).   If either the Eya gene pair or Six gene 
pair is knocked out, Pax3 is not activated in the hypaxial dermomyotome, 
resulting in a lack of limb musculature.  Interestingly, the Six and Eya genes are 
homologous to Drosophila genes that interact synergistically to control eye 
development.  In vertebrates, they still interact synergistically, but these specific 
members control migration, while other members control other organ 
development. 
 The lack of limb muscle phenotype in Pax3 mutants, or upstream 
activator mutants, is due to a migration defect.  Pax3 directly activates c-met, 
(Yang et al., 1996) a transmembrane tyrosine kinase receptor located on the 
cells that will migrate to the limb.  The ligand for this receptor is scatter 
factor/hepatocyte growth factor (SF/HGF) and is produced by cells of the limb 
bud (Bladt et al., 1995).  Removal of the c-met gene causes limb myogenesis to 
fail due to a lack of migration (Heymann et al., 1996) and ectopic activation of 
SF/HGF causes delamination of cells from the dermomyotome of interlimb 
somites, which normally do not produce lateral migratory precursors (Brand-
Saberi et al., 1996).  Pax7 and Lbx1 are also expressed in the migrating 
population of premyogenic cells.  Lbx1 is another target of Pax3, as its 
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expression is absent in Pax3 knockout embryos (Dietrich et al., 1998).  Lbx1 is 
only expressed in the lateral portion of the dermomyotome while cells are 
delaminating and is turned off slightly after the cell arrives in the limb field.  In 
Lbx1 knock out embryos, cells delaminate but do not migrate properly.  
Interestingly, there is a difference of phenotype between the forelimb and 
hindlimb muscles.  All hindlimb muscles are missing, while in the forelimb, only 
the extensor muscles of the forearm muscle are missing, indicating that Lbx1 
allows for cells to know their positional identity (Schafer and Braun, 1999).  Two 
other genes regulated by Pax3 in migratory precursors are Sp5 and CXCR4.  
Sp5 is a transcription factor and vertebrate homologue of the Drosophila gene, 
buttonhead.  The function of Sp5 is unknown, and no phenotype is produced 
when it is knocked out, but that may be due to the presence of seven other Sp 
factors (Sahara et al., 2007) that may compensate for the lack of Sp5.  CXCR4 is 
a chemokine receptor whose ligand, Sdf1, is expressed in the limb mesenchyme.  
In CXCR4 null mice, fewer progenitor cells reach the limb and there is an 
increase in apoptosis (Vasyutina et al., 2005).  Migratory cells also express Pitx2, 
a factor involved in the organization of the muscle anlagen once the progenitors 
reach the limb (Campbell et al., 2012). 
There are numerous factors expressed in myogenic progenitor cells 
before they leave the dermomyotome for the limb.  These cells may already be 
specified to myogenesis before arriving at the limb bud and activating the MRFs.    
The data in this thesis suggests these migratory cells are largely determined to 
myogenesis by factors present in the somite. 
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1.5 Transcriptional control of MyoD expression:   
 
Defining regulatory DNA elements of powerful transcription factors is of 
ultimate importance in understanding transcriptional pathways and in designing 
transgenic mouse lines.  Enhancer mutations may result in ectopic or altered 
expression of a gene and result in various pathologies depending on the specific 
gene (Bastianutto et al., 2002; Fuhrmann et al., 1999; Majumdar and Diamandis, 
1999).  It has been shown that MyoD-/- myoblasts serve as better transplant 
material than wild type myoblasts in mice (Asakura et al., 2007) which may be 
applicable to humans with muscle wasting diseases.    
There are only two known enhancer elements positively controlling MyoD 
expression.  These elements, the Core Enhancer (CE) and Distal Regulatory 
Region (DRR) lie 20kb and 5 kb upstream of MyoD, respectively.  In in vitro 
assays, these two enhancers exhibit activity in non-muscle cell types, contrasted 
by the precise control of MyoD expression in muscle lineages in vivo (Goldhamer 
et al., 1992).  In a developing embryo, there are probably repressive signals 
involved in MyoD expression.  One method to hide these positively acting control 
elements is the surrounding chromatin state.   
Enhancers were identified with constructs containing various restriction 
digest fragments of the 24 kb of human genomic sequence upstream of MyoD. 
The fragments were ligated to the chlorampenicol acetyltransferase (CAT) gene 
and stably transfected into various cell lines.  The amount of enzymatic activity in 
the cell lines represented the positive transcriptional ability of the DNA sequence 
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in question.  The most powerful fragment was F3, a 4kb segment containing the 
258bp CE (Goldhamer et al., 1992).  The CE and DRR share extremely high 
sequence similarity and genomic position between human and mice (Asakura et 
al., 1995; Goldhamer et al., 1995b).  The highly conserved DRR maintains all 
putative binding sites between the two species, which are four E-boxes 
(CANNTG) and two MEF-2 sites (Chen et al., 2001).  E-boxes are the DNA 
elements which bHLH transcription factor family members bind to, while MEF-2 
sites are bound by ‘myocyte enhancement factors’.  This family of transcription 
factors are calcium dependent transcription factors involved in cellular 
differentiation and proliferation (McKinsey et al., 2002).   The sequence 
similarities between the CE’s of humans and mice is approximately 90% and all 
putative binding sites are maintained,  including four E-boxes, an AP-1 site, and 
a H4TF-1 site (Goldhamer et al., 1995b).   
In the trunk, but not the limbs, Myf-5 lies genetically upstream of MyoD, 
and Pax3;Myf-5 double mutants fail to activate MyoD at all in the body 
(Tajbakhsh et al., 1997).  As mentioned previously, Six1/4 are upstream of Pax3, 
and in Six1/4;Myf-5 triple knockouts MyoD fails to activate as well (Relaix et al., 
2013). Another positive regulator of MyoD is SRF (serum response factor), and 
when inhibited in myoblasts or differentiating myotubes, the MyoD locus is rapidly 
shut down (Gauthier-Rouviere et al., 1996).  Another group of interacting factors 
is Sp1, YY1 and p300/CBP which are involved in chromatin remodeling 
(L'Honore et al., 2003; Roth et al., 2003; Wilson and Rotwein, 2006).  Cell-based 
assays and in vitro studies show a partnership between Fox03, Pax3, and Pax7 
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in the recruitment of RNA Polymerase II during the formation of the pre-initiation 
complex at the MyoD locus in myoblast cultures.  Fox03 is further implicated as a 
direct activator of MyoD through Fox03 knock out experiments, where MyoD is 
down regulated in regenerating muscle (Hu et al., 2008). 
 Recent findings regarding the transcriptional control of MyoD have shown 
many factors bind the CE directly.  Six1/4 regulates MyoD by binding the CE 
(Relaix et al., 2013), as does CLOCK and BMAL1, regulators of the circadian 
rhythm of MyoD expression (Zhang et al., 2011).  A limb specific activator of 
MyoD, Pitx2, has also been shown to bind the CE (L'Honore et al., 2010).   
Repression of MyoD expression has also been linked to the CE as Sim2 and 
YB1/p32 bind to the CE and repress the locus by both gain and loss of function 
experiments (Havis et al., 2012; Song and Lee, 2010). 
 In vitro cell culture analysis shows the histone variant H3.3, associated 
with transcriptionally active genes, is required to become associated with the CE 
for proper expression of MyoD in myoblasts and differentiating myotubes (Yang 
et al.), showing a role for epigenetic remodeling in the activation of the MyoD 
locus via the CE.   
 
1.5.1 Transgenic experiments: 
 
Using upstream regions of MyoD to drive lacZ or CAT expression have 
revealed two distinct elements, the Core Enhancer (Goldhamer et al., 1995a) 
(CE) and the Distal Regulatory Region (DRR) (Asakura et al., 1995).  24 
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kilobases of DNA sequence upstream of MyoD, containing the CE and DRR, 
drives lacZ expression in a spatio-temporal pattern that fully mimics MyoD mRNA 
expression.  Transgenic analysis indicates that the CE controls initiation of 
expression in newly forming myoblasts, while the DRR maintains expression in 
differentiating muscle.  CE-lacZ transgenic embryos exhibit activity in a manner 
similar to MyoD mRNA detection (Faerman et al., 1995; Goldhamer et al., 1992).  
DRR-lacZ transgene expression is limited to sites of differentiating muscle 
(Asakura et al., 1995).  In MyoD-/-;Myf-5-/- embryos, where no myoblasts form, the 
CE transgene is active while the DRR is not (Kablar et al., 1999) indicating the 
ability of the CE to initiate de novo MyoD expression.  The 2.5 kilobases 
immediately upstream of the transcriptional start site, including the proximal 
promoter does not contribute to specificity of expression.  The herpes simplex 
virus promoter exhibited nearly identical activity in myoblasts as the native MyoD 
promoter (Goldhamer et al., 1992).  The genomic region upstream of MyoD that 
had the highest activity was referred to as ‘fragment 3’ and contains the 258 base 
pair long Core Enhancer (Goldhamer et al., 1992).  When comparing the 
expression profile of the -24lacZ construct, which fully copies endogenous MyoD 
expression, to a similar construct which lacks the F3 fragment, there is only a 
delay in expression in the hypaxial myotome and limb buds up to E115, after 
which a normal expression profile is regained (Chen et al., 2001).    
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1.5.2 Deletion of Enhancers: 
 
Given the data showing the sufficiency of the CE and DRR to regulate 
MyoD expression, it is surprising to see these elements are not individually 
necessary.  In embryos lacking the CE, MyoD expression initiates properly in the 
epaxial lineage while there is a 1 day delay of expression in the branchial arches 
and limb buds (Chen and Goldhamer, 2004b).  This shows the initial timely 
activation of MyoD is CE dependent in only a subset early myogenic cells, and 
that ultimately, initiation of MyoD expression is CE independent.  Targeted 
removal of the DRR resulted in persistent MyoD expression in differentiating 
embryonic muscle, and this expression continues into adulthood, but with an 
approximate 60% reduction in mRNA levels, showing continued MyoD 
expression in differentiated muscle occurs without the DRR.  DRR knock out 
embryos exhibit a general reduction in MyoD levels at E10.5 (Chen et al., 2002).  
The differences between transgenic and knock out experimental results can be 
explained in two ways.  The first is that the CE and DRR have overlapping or 
compensatory abilities to regulate MyoD expression, such that when one is 
removed, only transient or minor defects are observed, due to the presence of 
the other enhancer.  The second is that another, uncharacterized DNA regulatory 
element exists.  In this thesis,  I resolve the two hypotheses by removing both the 
CE and DRR on the same chromosome.   Here, targeting of the CE for deletion 
was performed on mouse embryonic stem cells already lacking the DRR.  The 
expression profile of MyoD will be monitored in this new mouse line.   
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Myf-5 initiates MyoD expression in the body, as there is a 2 day delay in 
MyoD expression in Myf-5 mutants (Tajbakhsh et al., 1997).  MyoD expression is 
eventually rescued in Myf-5 mutants through a Pax3 dependent mechanism.  
Delayed MyoD expression is also seen in mice lacking Myf-5 and the CE or DRR, 
implying that both enhancers are responsive to Myf-5 dependent activation.  The 
kinetics of Pax3 dependent MyoD expression is the same in embryos with both 
enhancers present or embryos lacking either the CE or the DRR (Chen et al., 
2002) (Chen and Goldhamer, 2004a) (Tajbakhsh et al., 1997), demonstrating 
that neither the CE or DRR are exclusive targets of Pax3 dependent activation.   
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Chapter 2: The MyoD expressing lineage remains multipotent in the trunk 
but not the limbs of amyogenic embryos  
 
2.1 Abstract: 
 
 Using the MyoDiCre/+;R26lacZ/+ genetic cell labeling system, we have for the 
first time performed permanent lineage tracing of presumptive myoblasts in a 
genetic background where no myoblasts or muscle fibers form.  Recombined 
cells persist until birth and in the trunk, labeled cells change their fate and 
become cartilage, bone, and brown fat.  In the limbs, myogenic progenitors 
migrate properly and pattern themselves in a manner similar to wild type 
embryos.  Recombined limb cells do not express Pax7 or CD31 and only 
contribute to the loose connective tissue found in the limbs of amyogenic 
embryos.  The majority of these cells are surrounded by ER-TR7 positive 
extracellular matrix and many recombined cells express Tcf4, a transcription 
factor and fibroblast marker.  The results suggest the MyoD expressing lineage 
of presumptive trunk myoblasts can adopt alternate fates in the absence of 
primary myogenesis while limb progenitors appear to be fibroblastic. 
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2.2 Introduction: 
 
 MyoD is a pioneer transcription factor whose expression is restricted to 
the skeletal muscle lineage.   Forced MyoD expression from a retroviral vector in 
hepatocytes, adipocytes, and fibroblasts, transforms them into muscle cells 
(Weintraub et al., 1989)  MyoD belongs to a highly conserved myogenic family of 
basic helix-loop-helix (bHLH) transcription factors along with Mrf4 (Miner and 
Wold, 1990), Myogenin (Wright et al., 1989) and Myf-5 (Braun et al., 1989).  
These four factors are collectively referred to as the Myogenic Regulatory 
Factors (MRFs).  MyoD and Myf-5 function earlier in skeletal muscle 
development than Myogenin based on knock out experiments, while Mrf4 is 
expressed throughout myogenesis (Kassar-Duchossoy et al., 2004).  Single 
knock outs of either MyoD (Rudnicki et al., 1992) or Myf-5 (Braun et al., 1992) 
result in mild, transient delays in muscle development, and animals are born with 
skeletal muscle and are viable.  Embryos lacking MyoD, Myf-5 and Mrf4 develop 
no skeletal muscle, or their determined precursors, myoblasts (Rudnicki et al., 
1993) (Kablar et al., 2003) and the fate of these presumptive myoblasts is 
investigated here.  Myogenin-/- embryos exhibit severe differentiation defects, 
while myoblasts and primary myogenesis occurs normally (Venuti et al., 1995).  
Mrf4 knock out embryos show normal muscle formation, but there is a four fold 
increase in Myogenin expression (Braun and Arnold, 1995).  Initially, myoblast 
formation was thought to be controlled by MyoD and Myf-5 only, however, the 
Myf-5 knockout allele, Myf-5Neo, transcriptionally silenced the nearby Mrf4 gene.  
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The newer, Myf-5loxP allele allows for Mrf4 expression, and in MyoD-/-;Myf-5loxP/loxP 
embryos, some skeletal muscle is produced, but not enough to support life as 
embryos die at birth due to the absence of the diaphragm (Kassar-Duchossoy et 
al., 2004). It has never been demonstrated that cells that activate the MyoD locus 
in an amyogenic embryo can form other cell types, leaving the status of 
presumptive myoblast determination in question.   
 All skeletal muscle of the trunk and limbs arise from somites, transient 
embryonic structures flanking the neural tube.  MyoD and Myf-5 are expressed in 
a subset of somitic cells and form muscle, while the rest of the somite forms 
dermis and the axial skeleton (Christ and Ordahl, 1995).  MyoD and Myf-5 have 
been shown to function as master transcription factors, activating numerous 
muscle specific genes, but it has been proposed that myogenic progenitor cells 
are indeed determined before the onset of MRF expression (Tajbakhsh et al., 
1997), specifically in the migratory precursors of the limb (Kablar et al., 1999b).  
 Myogenic progenitors of the limb arise from the somites at limb level, but 
migrate directly to the limb bud without entering the myotome and without 
expressing any MRF’s (Tajbakhsh and Buckingham, 1994).  Whether this 
migratory cell population is determined in the somite without MRF expression, or 
migrate in a multipotent state and are determined upon MRF activation by 
signaling factor gradients present in the limb bud will be addressed.  Support for 
the view that migratory cells are determined in the somite includes selective limb 
muscle group hypoplasia in mouse mutants lacking genes expressed in the 
somite, ie; Lbx1 and the Six1/4 transcription factors, (Grifone et al., 2005) (Gross 
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et al., 2000) (Brohmann et al., 2000) CXCR4 (Vasyutina et al., 2005) and Pitx2 
(Campbell et al., 2012).  Also, limb bud grafts at interlimb levels induce the local  
somites to provide migratory cells to populate the ectopic limb muscle niche 
(Hayashi and Ozawa, 1995).  The dual population hypothesis is supported by 
gene knockout experiments, where MyoD-/- embryos exhibit a delay in hypaxial 
and limb myogenesis, while Myf-5-/- embryos have a delay in epaxial myogenesis 
(Kablar et al., 1997).  However, there is also data suggesting that premyogenic 
cells are not determined, and migrate to the limb, where endothelial or myogenic 
fates are determined by the signaling factors in the limb (Kardon et al., 2002a). 
 Our hypothesis is that multipotent cells of the somite become determined 
to myogenesis upon MyoD or Myf-5 activation.  To directly asses whether these 
genes function as determination factors, MyoDCre/-;Myf-5Neo/Neo mouse embryos 
containing a Cre-dependent reporter, will have cells that would have expressed 
MyoD permanently labeled via Cre-dependent recombination.  Recombination 
results in heritable, continuous reporter gene production allowing for long term 
lineage tracing.  Contribution of labeled cells to other lineages show the cells of 
the MyoD expressing lineage are not determined prior to MRF expression.   
 As described above MyoD-/-;Myf-5Neo/Neo embryos produce no myoblasts 
(Rudnicki et al., 1993).  The premyogenic population in these mice could have 
died, or changed fate based on observations of brown fat expansion in the back, 
and excess ‘amorphous loose connective tissue’ in the limbs of these double 
mutants (Rudnicki et al., 1993) (Rot-Nikcevic et al., 2006).  Transgenic 
experiments using Myf-5 regulatory regions to drive lacZ expression in 
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amyogenic embryos showed that the Myf-5 expressing population could change 
fate and contribute to cartilage of the axial skeleton.  Similar transgenic 
experiments using MyoD regulatory regions to control lacZ expression show the 
labeled population undergoing apoptosis, not contributing to other lineages, and 
the eventual loss of lacZ detection by E13.5 (Kablar et al., 2003).  Here, we show 
recombined cells of the MyoD expressing lineage to contribute to the axial 
skeleton and the expanded interscapular brown fat in MyoDCre/-;Myf-
5Neo/Neo;R26lacZ embryos and persist until birth, indicating that myogenic 
progenitors with an active MyoD locus remain multipotent in the absence of 
MyoD and Myf-5.     
 In contrast to the multipotent cells in the trunk, the limb population of 
recombined cells is associated with no distinct structures.  The premyogenic cells 
migrate to the limb and pattern themselves into structures similar to muscle beds. 
Recombined cells are found in the limb at birth, P0, and are only associated with 
the connective tissue found in large quantities in the limbs.  Immunofluorescent 
detection of Pax7, an upstream factor of the MRF’s, is lacking in mutant limbs.  
The recombined cells express Tcf4, a marker of fibroblastic cells (Mathew et al., 
2011), and are surrounded by a connective tissue extracellular matrix, that is 
positive for ER-TR7 antibody reactivity.  The fluorescent Cre dependent reporter, 
R26EYFP, was used in conjunction with fluorescent detection of these proteins in 
MyoDCre/-;Myf-5Neo/Neo;R26EYFP embryonic limbs.   
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2.3 Materials and Methods: 
 
Mouse breeding and genotyping 
 
 All mouse handling, breeding, and sacrificing were done in accordance 
with our IACUC animal care protocol. All separate lines were maintained by 
breeding to FVB mice. Experimental mice were generated by crossing 
MyoDiCre/+;Myf-5Neo/+ males with MyoDNeo/+;Myf-5Neo/+;R26lacZ/lacZ (Jax# 003309) or 
R26EFYP/EYFP females.  The MyoDiCre allele was detected by PCR using a forward 
primer (5′-GCGGATCCGAATTCGAAGTTCC-3′) that lies at the 3′ end of the 
icre/+2pA cassette and a reverse primer in intron 1 of MyoD (5′-
TGGGTCTCCAAAGCGACTCC-3′), generating a product of 149 bp.  MyoDiCre 
animals were bred to Myf-5Neo (Jax# 002522) animals to produce 
MyoDiCre/+;Myf5Neo/+ males. These males were bred to MyoDNeo/+;Myf-
5Neo/+;R26lacZ/lacZ females in order to produce MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ 
embryos with an estimated frequency of 1 in 16.  The MyoDNeo allele was 
detected with the forward primer 5’- TGGATGTGGAATGTGTGCGAG-3’ and the 
reverse primer 5’- TCACTGTAGTAGGCGGTGTCGTAG-3’ to create a 420 bp 
product.  R26lacZ was detected with the primers 5’-CCGAAATCCC 
GAATCTCTATC-3' and 5’-TTGGCTTCATCCACCACATAC-3' to create a 333 bp 
product.  The R26EYFP allele was detected using the primers 5’-
GACGTAAACGGCCACAAGTT-3’ and 5’-GGTCTTGTAGTTGCCGTCGT-3’.  
The Myf-5Neo allele was detected using the primers 5’-CGTTGG 
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CTACCCGTGATATT-3’ and 5’-  CAGCTCAGCTTTGTGTGCTC-3’ creating a 
410 bp product.  Myf-5 wild type allele used forward primer 5'-
TGAAGGATGGACATGACGGAC-3' and reverse  5'-TGACCTTCTTCAGG 
CGTCTACG-3' to create a 300bp product 
 All PCR reactions followed standard conditions and 30 cycles, with the following 
annealing temperatures; MyoDiCre, Myf-5Neo, MyoDNeo, and R26EYFP at 57oC and 
R26lacZ at 55oC.  
 
X-Gal Staining 
 
 Embryos were collected in PBS and fixed in 2% paraformaldehyde/ 0.25% 
glutaraldehyde/ in PBS pH 7.4 for 3 hours on ice, followed by several rinses in 
PBS for 2 hours to overnight, all in individual screw cap tubes.  Staining solution 
was prepared in PBS and contained 2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM 
K4Fe(CN)6, 0.01% Tween, 0.1% sodium deoxycholate and 0.1% X-gal. The 
staining solution was added to the embryos, and were placed in the dark at 37°C 
overnight with gentle rocking.  Following staining, embryos were washed in four 
changes of PBS over several hours and stored in 1% paraformaldehyde at 4°C. 
 
Paraffin Sectioning 
 X-Gal stained embryos were processed and paraffin embedded using 
standard procedures, then serially sectioned at 10μm and counter stained with 
Nuclear Fast Red (Vector labs)  
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Cryostat sectioning 
 
 Embryos were isolated and fixed with 4% paraformaldehyde for 3.5 hours 
at 4oC. The embryos were rinsed with cold PBS 4 times at 20 minutes each. The 
fixed muscle was processed through a sucrose gradient of 15% sucrose in PBS 
overnight, followed by 30% sucrose in PBS overnight. The processed tissue was 
placed into OCT compound and quickly frozen in dry ice cooled isopentane. The 
frozen tissue was cryosectioned at 10 microns and either stored at -80oC, or 
immediately processed for observation. 
 
Immunofluorescence 
 
 Slides for EYFP detection were blocked in PBSMT (2% powdered milk, 
0.5% Tween in PBS) followed by rabbit anti-GFP antibody at a 1:500 dilution.  
For Pax7 detection, slides underwent an antigen retrieval process of 6 minutes in 
-20oC methanol followed by boiling sodium citrate for 30 minutes.  Vector labs 
Mouse on Mouse block was used according to manufacturers recommendations 
(Vector # BMK-2202).   Pax7 supernatant (Developmental Studies Hybridoma 
Bank) was applied 1:1 in PBMST overnight at 4oC.  Tcf4 detection used only 
boiling sodium citrate for antigen retrieval and a standard block (1% BSA, 10% 
goat serum, 0.1% Tween in PBS).  Rabbit anti-Tcf4 (Cell Signaling 2569P) was 
applied at a 1:100 dilution in block, and incubated overnight at 4oC.     Perillipin 
was detected using standard block, with the rabbit anti-perillipin (Sigma P1783) 
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applied at a 1:500 dilution.  ER-TR7 (Santa Cruz sc-73355)  was detected using 
standard block and a 1:400 dilution and incubated overnight at 4oC.  Osterix was 
detected using a standard 2 hour block (1% BSA, 10% goat serum, 0.1% Tween 
in PBS) followed by an overnight incubation of the primary antibody, rabbit anti-
osterix (abcam# ab22552), at a 1:250 dilution.  The surface antigen, CD34, was 
detected using standard conditions with a 2 hour primary incubation, using rat-
anti CD34 (abcam# ab8185)at a 1:200 dilution. 
 Secondary antibodies were used at a 1:500 and dilution and are goat anti-
rabbit Alexafluor 488 (GFP) ( Invitrogen A11008), goat anti rat 568 (ER-TR7) 
(Invitrogen A11077) and for all other applications, goat anti rabbit 555 ( Invitrogen 
A21428) 
.   
Imaging 
 
Whole mount images were taken using a Lecia MZ FLIII and sections were 
viewed using a Nikon Eclipse E600.  Images were captured using a Spot 25.2 2 
Mp Color Mosaic camera using Spot Software V4.6 by Diagnostic Instruments.  
Images were modified using Photoshop CS2.  
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2.4 Results:   
 
2.4.1 Time Course of Cell Labeling During late Embryogenesis 
 
 MyoDiCre/Neo;Myf-5Neo/Neo embryos, referred to as 'mutant' for brevity,  
harboring a Cre-dependent reporter, were collected from E13.5 until birth, 
postnatal day zero, or P0.  E13.5 is the chosen starting point as it's when cells 
were 'lost' in previous experiments using lacZ transgenes for lineage tracing 
(Kablar et al., 2003).  Using a Cre-dependent reporter, we are able to 
permanently label any cell that has activated the MyoD locus, and this label is 
passed on to all daughter cells.  The Cre-dependent reporter, R26lacZ, was used 
for most developmental stages, while R26EYFP was used for the P0 time point due 
to a lack of reagent penetration during X-Gal staining and for the ease of 
fluorescent immunological detection of cell specific markers in conjunction with a 
fluorescent reporter.  Both reporter constructs are identical except for the reporter 
gene that gets activated following Cre mediated recombination.  E13.5 mutant 
embryos show a massive decrease in lacZ positive cells compared to 
phenotypically wild type embryos (Figure 2-1).  This result can be expected when 
no myoblasts form, causing a lack of cell proliferation and fusion into muscle 
fibers.  However, a relatively large number of β-Gal positive cells persist in 
embryos lacking all primary MRF activity in both the epaxial and hypaxial 
domains.     
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 Recombined cells in the developing cranial region were largely ignored in 
this analysis due to the many differences known to exist between head and body 
myogenesis, resulting in difficulties in interpretation of the results. These 
differences include head muscle progenitors arising from prechordal mesoderm, 
not from somites, unique regulation of MyoD (Tajbakhsh et al., 1997), and other 
distinct factors that drive myogenesis solely in the head, such as MyoR, Pitx2, 
Tbx1, and Capsulin (Lu et al., 2002) (Noden and Francis-West, 2006) (Grifone 
and Kelly, 2007).   
 Embryos collected at E14.5, 15.5, 18.5, and newborns, denoted P0, show 
that recombined cells persist (Figure 2-2 A and B), and do so until E18.5 (Figure 
2-2 C).  P0 embryos contain the enhanced yellow fluorescent protein gene, 
EYFP as a readout of Cre-dependent recombination.  Due to the size of newborn 
mice, and low fluorescent levels of EYFP, whole mount images are not 
informative and have been  omitted.  Identification of cell position and cell type 
marker expression in the newborn mice is achieved by cryosectioning and 
immunofluorescent antibody detection. MyoD is a lineage specific marker, and 
finding cells that normally would have expressed MyoD changing their fates and 
not undergoing apoptosis, provides firm evidence that the MyoD expressing 
lineage of presumptive myoblasts remains multipotent in the amyogenic embryo. 
 We have shown that presumptive myogenic cells persist and do not 
apoptose in the absence of MRFs.  Previous lineage tracing experiments (Kablar 
et al., 1997; Kablar et al., 1999a) were inconclusive because reporter gene 
expression was only temporary, and the absence of labeled cells meant either 
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the transgene was silenced, or the cells died.  Using a permanent cell labeling 
system, we now know the absence of signal was due to transcriptional silencing 
of the reporter transgene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
 
Figure 2-1 
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Figure 2-1.  X-Gal staining in E13.5 wild type and mutant embryos  
 
Observation of labeled myoblasts and muscle fibers in phenotypicaly normal 
MyoDiCre/+;R26lacZ embryos (A) and cells that have activated the MyoD locus in 
MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos (B).  There is a marked decrease of 
recombined cells in the mutant, particularly in the trunk.  Branchial arch derived 
myogenic progenitors activate the MyoD locus and remain in large numbers in 
the mutant (yellow arrows).  Labeled cells in the limbs of mutants maintain a 
physical pattern reminiscent of wild type in the fore (red arrows) and hind limbs 
(green arrows). 
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Figure 2-2 
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Figure 2-2.  Time course of recombined cell staining during late embryonic 
and fetal development in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ mice 
 
Labeled cells persist through E18.5 in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos.  
Limb staining shows a clear progression of recombined cell patterning from one 
developmental stage to the next (red arrows).  Quantity and patterning of labeled 
cells was consistent between embryos at similar developmental time points.  
Recombined cells in the trunk are difficult to see due to their low number and 
density.  
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2.4.2 Fate changes in recombined cells in the trunk of E13.5 
MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos 
  
 In the absence of the primary MRF's, recombined cells contribute to 
cartilage in the forming scapula (Figure 2-4 A, red arrow) and vertebra (Figure 2-
4 B red arrow) and are histologically identical to their non recombined neighbors.   
While many labeled cells contribute to the endochondral ossification process, 
many more remain as loose connective tissue, found in place of skeletal muscle 
surrounding the bones (Figure 2-4 A and B, black arrows).  In MyoDiCre/+;R26lacZ 
embryos, recombined cells contribute only to skeletal muscle, and their precursor 
myoblasts. 
 Interscapular brown fat pads, a major source for non-shivering 
thermogenesis in neonates, from both mutant and wild type embryos were 
isolated and sectioned.  A large number of recombined cells are found in the fat 
pads of mutant embryos (Figure 2-4 C) and appear histologically 
indistinguishable from their non-recombined neighbors.  Interestingly, in the 
dorsal portion of the trunk, there is a large amount of fluid underneath the skin, 
making it prone to tearing.  Sectioning embryos shows empty pockets where 
cells are absent.  No recombined cells were found in the fat pads of  
MyoDiCre/+;R26lacZ embryos.    
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Figure 2-3 
 
MyoDiCre/+;R26lacZ MyoDiCre/-;Myf-5-/-;R26lacZ
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Figure 2-3.  Recombined cell patterning in forelimbs 
 
10 μm transverse paraffin sections of limbs in E13.5 mutant (B) and wild type (A) 
embryos.  In A, migratory myogenic precursors populate the limbs and pattern 
themselves into developing muscle beds.  In B, recombined cells do not undergo 
myogenesis, but position themselves in a manner similar to myoblasts.  Red 
arrows indicate the medial portion of the limb, while black arrows indicate the 
lateral portion. The distal portion of the limb is located at the bottom of the image.  
Nuclear fast red used as counter stain. 
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2.4.3 Limb Phenotype in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos 
 
 Myogenic progenitors of the limb in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ 
embryos not only migrate from limb level somites properly, they also pattern 
themselves in a manner similar to wild type embryos (Fig 2-3), and these cells 
persist past E18.5 (Figure 2-2 C) until birth (Figure 2-10 B and E).  The limb 
patterning results are reproducible at each stage, indicating precise activation of 
the MyoD locus in the limbs.  It has previously been shown that cells migrate to 
the limb prior to MRF expression, so this result is not surprising.  The fact that 
these cells persist, and continue to maintain a reproducible pattern until birth is 
novel.  Labeled cells do not contribute to any identifiable structures in the limb, 
such as bone and skin.  
 The amyogenic phenotype has been reported in other studies, but 
descriptions of the limb have been lacking.  With no muscle in the limb, 
fibroblasts proliferate and make up almost the entire volume of the limb.  These 
delicate, fibrous cells are not durable and prone to damage during skinning, 
embryo manipulation.  During sectioning, the delicate nature of the tissue causes 
section tearing. It is possible to see the bones of the limb through this delicate 
tissue (Fig 2-7B red arrows). Quality sectioning of embryos is difficult due to the 
lack of a strong cellular structure.  In the forelimbs, the radius and ulna are much 
closer together in mutant versus wild type embryos (Fig 2-8), as are the tibia and 
fibula in the hindlimbs.  
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Figure 2-4 
 
Scapula                      Vertebra         Interscapular  Brown Fat 
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Figure 2-4.  Labeled cells contribute to non myogenic lineages in the trunk  
 
10 μm paraffin cross sections of E13.5 MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos. 
The cartilage condensations of the developing scapula (A) and vertebra (B) 
contain lacZ+ cells only in MyoDiCre/Neo;Myf-5 Neo/Neo;R26lacZ embryos (red arrows).  
Recombined cells also populate the area surrounding the developing bone (black 
arrows).   Labeled cells are also present in the interscapular brown fat pads from 
E13.5 to birth (C).     
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Figure 2-5 
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Figure 2-5.  Recombined cells in the trunk contribute to bone at P0 
 
Serial 10μm cryosections of MyoDiCre/Neo;Myf-5Neo/Neo;R26EYFP embryo (A-D and 
H-M).  Panels A-D show Osterix positive bone cells (red) of the rib rudiments.  
Phase contrast image (A) is characteristic of bone morphology in phase panels G, 
J, and M.  Dapi (C, E, H, K) was used to visualize nuclei.   Panels F, I, and L 
show EYFP+ cells in different rib rudiments.   Panels E-G are from a 
MyoDiCre/+;R26EYFP embryos and show no EYFP detection in bone, only in the 
surrounding muscle.  Scale bars represent 30 μm. 
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Figure 2-6 
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Figure 2-6. Recombined  cells contribute to brown fat in P0  
MyoDiCre/Neo;Myf-5Neo/Neo;R26EYFP animals 
 
10 μm serial cryosections of MyoDiCre/+;R26EYFP  (A and B) and  MyoDiCre/Neo;Myf-
5Neo/Neo;R26EYFP newborns(C and D).  Perilipin (red in A and C), a fat specific 
marker, was used along with section location to identify interscapular brown fat 
pads.  In serial sections from MyoDiCre/Neo;Myf-5-/-;R26EYFP embryos, EYFP+ cells 
contribute to perilipin positive brown fat (C).  Dapi used to visualize nuclei. Scale 
bar represents 30 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
2.4.4 Fate of recombined cells in the trunk and limbs at P0 in 
MyoDiCre/Neo;Myf-5Neo-Neo;R26EYFP embryos 
 
 There are differing results in the fate of labeled cells in the trunk versus 
the limbs in mutant embryos.  In the trunk, fate changes take place, and cells that 
would normally form muscle express perillipin and contribute to brown fat (Fig 2-
6),  while others are osterix positive and contribute to bone (Fig 2-5). Due to the 
low level of EYFP expression, antibody detection is used to enhance the signal.  
Serial cryosections were used for antibody detection of other markers.  
 In the limb, labeled cells do not contribute to bone or vasculature, and 
instead, the vast majority remain clustered in a 'rod' aligned along the proximal-
distal axis (Fig 2-7) with some recombined cells remaining outside of the rod.  
Some EYFP positive cells express Tcf4, a fibroblastic marker (Mathew et al., 
2011), and are surrounded by an ER-TR7 (Van Vliet et al., 1986) positive extra 
cellular matrix (Fig 2-9).  It can be safely assumed that these cells have become 
fibroblastic or are stalled in their developmental pathway.    
 Not all of the EYFP+ cells express Tcf4, so if some of our cells of interest 
remain poised for myogenesis, they should express the early myogenic marker, 
Pax7 (Halevy et al., 2004).  However, no Pax7 positive cells were found in 
mutant limbs, either in the EYFP positive or negative areas (Fig 2-10 E and F).  
In wild type limbs, Pax7 is expressed in satellite cells, the tissue specific stem 
cell used in muscle growth and repair (Fig 2-10 A and B).   
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 While no EYFP+ cells were found in the bones of the limb, and some 
EYFP+ cells are phenotypically fibroblastic, we investigated whether recombined 
cells could contribute to endothelial vascular cells, the other major limb cell type 
present.  In the mutant limbs, there is a severe reduction in the amount of CD31+ 
vasculature (Fig 2-10 G and H) in comparison to wild type (Fig 2-10 C and D).  Of 
the rare CD31+ cells found in the mutant, none of them were EYFP+.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62 
   Figure 2-7 
 
A
B
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Figure 2-7. Forelimb close up of E18.5  MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ 
embryo 
 
Limbs contain no muscle fibers and are largely transparent, allowing visualization 
of limb bones (red arrows show radius and ulna in B).  (B) is a higher 
magnification image of the limb in (A).  Loose connective tissue comprises the 
majority of soft tissue in the limb and is quite fragile.  In (A), the green arrow 
indicated the distal paw, while red arrow points to proximal elbow. 
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Figure 2-8 
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Figure 2-8. Paraffin sections of E18.5 forelimbs 
 
10 μm paraffin sections of MyoDiCre/+;R26lacZ (A) and MyoDiCre/Neo;Myf-
5Neo/Neo;R26lacZ (B) E18.5 forelimbs.  The distance between the radius and ulna is 
smaller in B compared to A.  In both panels, blue cells have historically activated 
the MyoD locus.  The thick 'rod' of cells seen in Figure 2-7 is shown in cross 
section (in B, red circle).  Other, less concentrated, β-Gal positive cells are also 
seen in B (red arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
Figure 2-9 
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Figure 2-9. Fibroblastic recombined cells in P0 limb sections  
 
EYFP+ cells in the limb of MyoDiCre/+;R26lacZ embryo cryosections (A-D) show 
EYFP+ skeletal muscle and position of fibroblasts. MyoDiCre/Neo;Myf-
5Neo/Neo;R26EYFP embryos (E-H) show the dense packing of cells seen in Figures 
2-7 and 2-8.  In serial sections, EYFP+ areas are surrounded by the extracellular 
matrix protein, ER-TR7 (H) and some cells express the fibroblastic marker Tcf4 
(G).  Scale bar represents 30 μm. 
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Figure 2-10 
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Figure 2-10. Recombined cells in mutant embryos do not express Pax7 or 
CD31 at P0 
 
Pax7, a marker of pre and early myogenic cells, is found only in 
MyoDiCre/+;R26EYFP  sections (A and B) and nowhere in MyoDiCre/-;Myf-
5Neo/Neo;R26EYFP sections (E and F).  CD31, an endothelial cell marker, is greatly 
reduced in mutant (G and H) versus control (C and D) limb sections.  Also, no 
EYFP+ cells in the mutant were CD31+.  Scale bar represents 30 μm. 
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2.5 Discussion: 
 
 MyoD is such a potent transcription factor that its trans-activation domain 
has been fused to other DNA binding domains in order to increase the efficiency 
of forming iPS cells (Hirai et al., 2012) and cardiomyocytes (Hirai et al., 2013) in 
culture.   MyoD has incredible chromatin remodeling abilities and activates 
transcription at many downstream loci.  MyoD directly recruits the SWI/SNF 
chromatin remodeling complex to specific sites(de la Serna et al., 2005), leading 
to muscle specific E box binding (an excellent review  (Tapscott, 2005)).   
  However, there has been no classical experimental evidence proving 
MyoD is a determination factor.  To prove a cell is determined, transplantation of 
the cells in question to an ectopic site in the embryo is performed.  If the 
transplanted cells maintain their original identity, they were determined to a fate 
at the time of transplant.  Myoblast transplants in mice to ectopic sites form 
skeletal muscle, but myoblasts have already expressed MyoD, and the results 
are not informative (Irintchev et al., 1998).  Somite rotation experiments in the 
developing chicken embryo show that cells of the somite are plastic in newly 
formed somites, as well as the two sets located cranially (Dockter and Ordahl, 
2000).  Some of the cells in the somite have already expressed Myf-5, but not 
MyoD, at the time of rotation, but early in somite maturation, appropriate gene 
expression requires continuous exposure to signaling centers in the embryo 
(Pownall et al., 2002).   
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 The questions addressed here are if the MyoD expressing lineage 
remains multipotent in the absence of myogenesis and if the lineage remains 
multipotent in epaxial (trunk) and hypaxial (limb) myogenic fields.  Given the 
complex, and still largely unknown, upstream activators of MyoD, cells may be 
determined by one or more upstream factors before the onset of MyoD 
expression and myogenesis.    Here, we analyzed the fate of cells that have 
activated the MyoD locus, in the absence of MyoD and the other primary MRFs, 
while all upstream signaling pathways are unperturbed. 
 Previous lineage tracing studies using transgenes have only followed Myf-
5lacZ+ cells through E15.5, and MyoDlacZ+ cells to E13.5 in amyogenic 
embryos (Kablar et al., 2003; Kablar et al., 1999a).  The conclusion from these 
reports, along with an increase in the number of apoptotic cells, was that cells of 
the MyoD lineage apoptose and do not contribute to other lineages, while cells in 
the Myf-5 lineage remain and contribute to other cell lineages, such as cartilage.  
Using Cre recombinase we show the MyoD lineage persists and the loss of 
signal was due to transcriptional silencing of the transgene.  Our current findings 
demonstrate that myogenic progenitors in the trunk abandon myogenesis before 
E13.5, and instead are able to progress down different lineages, such as 
cartilage, bone, and brown fat.  In the limbs, our labeled population survives and 
contributes only to the fibroblastic-like cells of the limbs.   
 A common hypothesis was that MyoD and Myf-5 control myogenesis in 
two different cell lineages as opposed to single cells expressing both factors.  
Recent supporting experiments used diphtheria toxin (DTA) driven lineage 
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ablation, to kill Myf-5 expressing cells, yet skeletal muscle still forms (Haldar et 
al., 2008) demonstrating that a Myf-5 independent lineage exists.  However, 
when the MyoD expressing lineage is ablated, no muscle remains in embryos at 
E18.5 (preliminary data in chapter 4) (Wood et al., 2013).  Also, it has been 
shown that all satellite cells,  muscle specific stem cells, express MyoD prenatally 
(Kanisicak et al., 2009).  Taken together, these results show that all cells in the 
myogenic lineage express MyoD, while not every cells expresses Myf-5.  This 
means that the fate changes seen in Myf-5lacZ amyogenic embryos are 
accounted for in this study.  Our results show that cells that have activated the 
MyoD locus persist until birth, and take on different fates.   
 There are differing observations of cell fate plasticity in trunk versus limb 
myogenic progenitor cells.  These two populations are quite different, as trunk 
myogenesis begins earlier and limb progenitors migrate directly from the 
dermomyotome, without entering the myotome.  Cells that populate the limb 
express several genes that trunk progenitors do not, such as c-met and Lbx1 
(Mennerich and Braun, 2001).  Expression of  the transcription factors Pax3, 
Pitx2, Dach2, Eya2, and Six1/4 remains only in the hypaxial edge of the 
dermomyotome and in migratory limb progenitors (Grifone et al., 2007; Heanue 
et al., 1999; Kardon et al., 2002b; L'Honore et al., 2010).   These migratory cells 
don't express any MRFs until they reach the limb field.  As they are the only 
source of skeletal muscle for the limbs, they are possibly already specified for the 
myogenic fate as they leave the somite.  Trunk myoblasts and bone progenitors 
share a common somitic origin, while the bones of the limb derive from lateral 
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plate mesoderm.  This may explain the inability of recombined limb cells to 
contribute to osteogenesis.  The other fate change, recombined brown fat cells, 
may be linked to a common origin as well.  Prdm16 has been shown to control a 
switch between skeletal muscle and brown fat fate decisions, such that over 
expression of Prdm16 can convert myoblasts to brown fat (Seale et al., 2008).  
Brown fat progenitors have been shown to activate the Myf-5 locus (Shan et al., 
2013), and MyoD;Igf2 double null animals have an increase in brown fat 
development (Borensztein et al., 2012).   However, limb myogenic progenitors 
share a dermomyotomal origin with limb endothelial cells, but there was no fate 
change noted.  This may be due to specification in the somite followed by 
signaling molecules in the limb regulating fate decisions (Kardon et al., 2002a).   
 As previously stated, the MyoDiCre labeling system labels the entire 
embryonic population of myoblasts, while Myf-5Cre does not.  While this project   
was underway, this fact was not yet known.  Therefore, MyoDiCre/Neo;R26lacZ 
embryos were analyzed for any fate changes in the absence of MyoD only, as 
MyoD and Myf-5 might control myogenesis in two different cell lineages.  All 
recombined cells contributed to muscle in these embryos, and the data was 
excluded.  In retrospect, if the DTA experiments reflect the actual biology, then 
some premyogenic cells do not express Myf-5, and are dependent on MyoD or 
Mrf4 for access to the myogenic program.  In MyoDiCre/Neo;R26lacZ embryos, MyoD 
expressing cells do not contribute to other fates, perhaps due expression of Myf-
5 and Mrf4.  If there is a MyoD dependent myogenic lineage, its close proximity 
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to Myf-5 and Mrf4 expressing myogenic cells may lead to fusion into the forming 
muscle fibers. 
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Chapter 3: Embryonic transcriptional regulation of MyoD is largely 
independent of the Core Enhancer and Distal Regulatory Region  
 
3.1 Abstract: 
 
Transgenic experiments identified two enhancers of the muscle specific 
gene, MyoD.  These enhancers, called the core enhancer (CE) and distal 
regulatory region (DRR), control the initiation and maintenance of expression, 
respectfully.  However, deletion of CE results in only a mild expression delays in 
the limb buds and branchial arches, while deletion of the DRR results in lowered 
postnatal expression levels.  Here, we have removed both enhancers via 
homologous recombination to address the functional redundancy between the 
two enhancers.  In homozygous embryos with both enhancers removed 
(MyoDΔCEDRR/ΔCEDRR),  MyoD expression continues with a one day delay in 
hypaxial lineage expression, reminiscent of CEloxP/loxP embryos who only lack the 
CE (Chen and Goldhamer, 2004a). An even milder delay in early myotome 
expression is the only novel phenotype in MyoDΔCEDRR/ΔCEDRR embryos.  In 
additon, the removal of the 15 kb of DNA between the CE and DRR, 
(MyoDΔCE15DRR/ΔCE15DRR) resulted in identical expression kinetics.  In the absence 
of Myf-5, MyoD expression is dependent on Pax3.  The rescue kinetics in these 
new lines are identical to wild type embryos.    Ultimately, the CE and DRR are 
not necessary for largely normal MyoD expression. 
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In an attempt to identify the new enhancers, a genomic approach was 
taken to analyze 2 Mbp surrounding MyoD for conserved sequences across 
species and for transcriptionally positive epigenetic markers.  We found the 
introns of MyoD contain positive epigenetic marks, are conserved across species, 
and have putative binding sites for several  transcription factors. 
 
3.2 Introduction:  
 
MyoD is a pioneer transcription factor that activates genes necessary for 
myogenesis in a temporally regulated manner, remodels chromatin, promotes 
proliferation and orchestrates a complex cellular response. Two excellent reviews 
can be found here (Tapscott et al. 2005,  Singh et al. 2013).    
MyoD is one of four members of the myogenic family of bHLH 
transcription factors that control embryonic and postnatal myogenesis.  Myoblast 
formation is controlled by MyoD and Myf-5, and to a lesser extent Mrf4, while 
myogenic differentiation and fiber formation is performed primarily by Mrf4 and 
Myogenin.  In the original MyoD-/-;Myf-5-/- embryos, myoblasts fail to form and 
myogenesis fails (Rudnicki et al., 1993).  However, this phenotype was partly due 
to transcriptional silencing of the Mrf4 locus by the Myf-5Neo allele.  When a 
different Myf-5 knockout allele is used, Myf-5loxp, Mrf4 expression is not 
compromised and some Myosin Heavy Chain positive cells form, but myogenesis 
is not robust enough to produce viable animals (Kassar-Duchossoy et al., 2004).   
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In order to understand the transcriptional regulation of MyoD, we must 
define it's enhancer regions.  Enhancer mutations can result in ectopic or altered 
gene expression that results in various pathologies depending on the specific 
gene of interest (Sur et al., 2012) and reviewed (Pennacchio et al., 2013).  It has 
been shown that MyoD-/- myoblasts serve as better transplant material in mice 
than wild type myoblasts (Asakura et al. 2007) and this finding may be applicable 
to humans with muscle wasting diseases.  If MyoD can be temporarily 
transcriptionally repressed during in vitro culture and expansion of patients 
myoblasts, a useful number of cells can be generated for transplant.   
Early knowledge of the upstream transcriptional regulators of MyoD 
expression comes from gross embryonic disruption of signaling centers, such as 
the notochord, neural tube, and surface ectoderm, impacting BMP, Shh and Wnt 
signaling pathways. (Reviewed by (Borycki and Emerson, 2000)).  Removal of 
the neural tube from avian embryos causes MyoD expression to end, possibly 
due to a lack of Wnt signaling (Bober et al., 1994a).  Members of the Wnt family 
of transcriptional activators are expressed in the neural tube, Wnt1 (Tajbakhsh et 
al., 1998), and surface ectoderm, Wnt7a (Cossu et al., 1996), and these two Wnt 
factors are shown to activate myogenesis in mesodermal cells.  Sonic Hedgehog 
(Shh) is expressed in both the notochord and floorplate of the neural tube and 
has been shown to be promote myogenesis, while Shh-/- embryos exhibit 
myogenic defects (Marcelle et al., 1999).  However, there has been no evidence 
of direct binding of these factors to the MyoD locus.  The Wnt and Shh pathways 
may indirectly control MyoD expression. 
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To define the cis-acting DNA elements directing MyoD expression, 
transgenic experiments using human sequence of the upstream regions of MyoD 
to drive lacZ or CAT (chloramphenicol acetyltransferase) expression were 
performed.  A transgene containing 24 kb of DNA upstream of the human MyoD 
gene was fused to the  CAT gene and its transcriptional activity was tested in 
23A2 myoblasts (Goldhamer et al., 1992).  CAT was expressed at high levels, 
and the construct was reduced to smaller fragments to isolate discrete enhancers.  
A 4 kb portion called Fragment 3 (F3), lying 22 to 18 kb upstream of MyoD, 
directs reporter gene expression almost identically to the entire 24 kb construct.  
Removal of F3 from the original construct created -24ΔF3CAT, and expression 
levels dropped to baseline levels (Chen et al., 2001).  -24lacZ and -24ΔF3lacZ 
constructs containing human DNA were also used to generate transgenic mouse 
embryos for in vivo analysis.  -24lacZ embryos exhibited reporter gene 
expression in mouse embryos in a pattern that fully mimics endogenous MyoD 
mRNA expression (Goldhamer et al., 1992).  -24ΔF3lacZ  embryos exhibit delays 
and reduction of reporter expression at all myogenic locations (Chen et al., 2001) 
while F3lacZ constructs direct reporter gene expression in a manner faithful to 
MyoD mRNA in mouse embryos (Faerman et al., 1995).  At the center of F3 is a 
258bp element, the core enhancer (CE), largely responsible for the 
transcriptional activity of F3 (Goldhamer et al., 1995).  Similar experiments 
identified a second enhancer, the distal regulatory region (DRR), 4kb 5' to MyoD 
(Asakura et al., 1995).  The CE and DRR share sequence homology between 
mice and humans, explaining how human noncoding regions are capable of 
 82 
driving proper expression in mouse embryos.  The DRR is 71% identical, and all 
putative binding sites are preserved (Chen et al., 2001).  Mutation of the YY1 and 
SRF binding sites in the DRR eliminates its enhancer activity in vitro (L'Honore et 
al., 2003).  The CE is 87% identical and also maintains binding sites across 
species (Goldhamer et al., 1995).  Transgenic analysis indicates that the CE 
controls initiation of expression in newly forming myoblasts, while the DRR 
maintains expression in differentiating muscle.  In support of this idea, in MyoD-/-
;Myf-5-/- embryos, where no myoblasts form, the CE transgene is active while the 
DRR is not (Kablar et al., 1999).  The drawbacks to these transgenic experiments 
are that the genomic regions of interest are assayed outside of their normal 
chromosomal context, and the results show only the sufficiency of these DNA 
elements in driving transcription of the reporter gene. 
The necessity of the CE and DRR has been investigated by deletion of 
either enhancer from the mouse genome. Deletion of the CE resulted in MyoD 
expression initiating properly in the myotomes, while a 1 day delay of expression 
was observed in a subset of the hypaxial lineage, specifically the limb buds and 
branchial arches (Chen and Goldhamer, 2004b).  This shows the CE is not 
necessary for initial activation of MyoD and that the CE controls timely activation 
in only a subset of myogenic cells.  Targeted removal of the DRR resulted in a 
decrease of MyoD expression at E10 only.  In adult muscle, MyoD expression 
continues, but with an approximate 60% reduction in mRNA levels, showing 
continued MyoD expression in differentiated muscle occurs without the DRR, 
albeit at reduced levels (Chen et al., 2002).  
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 In summary, 24 kb of human DNA sequence upstream of MyoD can drive 
high levels of reporter gene expression in myoblasts in vitro and in developing 
mouse embryos.  The same is true for CE and DRR driven transgenes as well.  
However, when the mouse equivalent of either of these enhancers are deleted, 
only mild changes in MyoD expression are seen.  In -24ΔF3lacZ embryos, 
reporter gene expression shows a much more severe delay in limb expression 
than does MyoD expression in embryos lacking only the CE.  Interestingly, there 
is no delay in branchial arch expression in -24ΔF3lacZ embryos, unlike embryos 
lacking the CE.  These somewhat contradictory findings along with the difference 
between necessity and sufficiency of these enhancers regions may lie in the 
species difference between the transgenic and knock out experiments.  Another 
possibility is that in the mouse, the CE and DRR have overlapping or 
compensatory abilities to regulate MyoD expression.  The last possibility is that 
one or more uncharacterized DNA regulatory element exists.  The best way to 
resolve the last two hypotheses is to remove both the CE and DRR on the same 
chromosome.   In this chapter, targeted deletion of the CE was performed in 
mouse embryonic stem cells lacking the DRR.    
A finer point of MyoD regulation investigated is the target of Pax3 
dependent rescue of MyoD expression.  MyoD expression in the body is initially 
Myf-5 dependent, and there is a delay in MyoD expression in Myf-5 knock out 
embryos (Tajbakhsh et al. 1997) (Kassar-Duchossoy et al., 2004).  MyoD 
expression is eventually rescued through a Pax3 dependent mechanism, as 
MyoD is not activated in the trunk or limbs of Myf-5/Pax3 double mutants 
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(Tajbakhsh et al., 1997).  It should be noted however, that in Pax3 mutant 
embryos, myogenic progenitors fail to migrate from the somite to the limb, and 
therefore may not receive the proper signals to activate MyoD (Daston et al., 
1996b).  A lacZ transgene, driven by the CE and promoter of MyoD called 258/-
2.5lacZ is active in Myf-5 null embryos and is a target of Pax3 dependent rescue.  
Mutation of two, 15bp segments toward the 3' end of the CE results in poor lacZ 
expression in the trunk in Myf-5 null embryos (Chen and Goldhamer, 2004a).  
Taken together, the CE is responsive to the Pax3 pathway through a 30 bp 
internal segment.  This internal segment is also a target of Myf-5 activation, due 
to a lack of lacZ expression in Pax3 null embryos (Kucharczuk et al., 1999).    As 
mentioned above, the CE is sufficient to drive lacZ expression in either the 
absence of Myf-5 or Pax3, but the CE is not necessary.  The kinetics of Pax3 
dependent MyoD expression is the same in wild type embryos or those lacking 
the CE or the DRR, demonstrating that neither the CE nor the DRR are exclusive 
targets of Pax3 dependent rescue of MyoD expression (Chen et al., 2002; Chen 
and Goldhamer, 2004b).  Analysis of MyoD expression in the new mouse lines 
lacking both MyoD enhancers and Myf-5 will asses whether there are other 
elements responsive to the Pax3 pathway.   
In order to fully understand the transcriptional control of MyoD, the 
regulatory regions must be identified and characterized.   Because of the 
conflicting data from lacZ transgenic and knockout experiments in mice regarding 
the function of each enhancer, a CE and DRR double enhancer knock out line 
has been created, called MyoDΔCEDRR.  MyoDΔCEDRR/ΔCEDRR  embryos are assayed 
 85 
for their MyoD expression profile to uncover any redundant transcriptional control 
abilities of the enhancers.   
Given that 24kb of DNA upstream of MyoD drives transgene expression 
faithfully, and because other enhancers may exist between the CE and DRR, the 
15kb of genomic DNA between the two enhancers, including the enhancer 
elements themselves, are deleted in a related mouse line named MyoDΔCE15DRR  
 The two homozygous mutant lines, MyoDΔCEDRR/ΔCEDRR and 
MyoDΔCE15DRR/ΔCE15DRR exhibit the same MyoD expression profile as CE single 
knockouts, aside from a slight myotomal delay in expression.  This shows at least 
one unknown enhancer exists, and it does not lie in the 15 kb of genomic DNA 
between the two enhancers.  MyoDΔCE15DRR/ΔCE15DRR  and MyoDΔCEDRR/ΔCEDRR 
embryos also exhibit the same kinetics of Pax3 dependent rescue of MyoD 
expression as wild type embryos. 
Knowing that other enhancers are controlling almost all aspects of 
embryonic MyoD expression, a computer database search was performed in an 
effort to identify evolutionarily conserved sequences and active histone 
modifications in the 2Mbp surrounding the MyoD locus.  The results implicate the 
introns of MyoD as possible enhancers due to conservation across species, 
positive epigenetic modifications, and numerous binding sites for relevant 
transcriptional activators. 
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3.3 Materials and Methods: 
 
MyoD CE targeting vector creation 
 
All plasmid backbones are pBluescript II SK+ (Stratagene). A floxed 
(flanked by loxP sites) PGKNeo cassette was excised from the plasmid, ploxP-
neo-1 (provided by Dr. Marissa Bartolomei) via EcoRI (5’ end) and XhoI (3’ end) 
double restriction enzyme digest. The resulting overhangs were filled in by 
Klenow (New England Biolabs cat# M0212S). This fragment was inserted and 
ligated in reverse orientation between two FRT sites in the loxP2-FRT2/BSIIPSK 
plasmid (provided by Dr. Mazakazu Yamamoto), previously blunt end linearized 
by EcoRV.   
The FRT-loxP-PGKneo-loxP-FRT (FLneoLF) portion of the plasmid was 
removed via NotI and EcoRI sequential digests and inserted into p5’enh3’EB 
(created by Dr. Jennifer Chen (Chen and Goldhamer, 2004b)).  This plasmid 
contains 7.3 kb of mouse genomic DNA containing the CE.  The 258 bp core 
enhancer fragment was excised by BamHI and EcoRI sequential digests.  The 
FLneoLF fragment was inserted and ligated into the space previously occupied 
by the CE, and was flanked by 3.7kb of genomic DNA on the 5’ (upstream) side 
and 3.6kb on the 3’ (downstream) side.  The resulting ligation product was called 
p5’FLneoLF3’.  A thymidine kinase (tk) cassette was added to the 3’ end of 
p5’FLneoLF3’ at the XhoI site.   
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The plasmid, p5’FLneoLF3’tk, was grown in NM544 electrocompetent 
bacteria and the plasmid was isolated using Qiagens EndoFree Maxi Kit, as per 
manufacturers’ instructions.    
   
Mouse chimera creation 
 
The targeting vector was linearized by NotI and suspended in TE at a 
concentration of 1µg/µl and delivered to the University of Connecticut Health 
Center (UCHC) Gene Targeting and Transgenic Facility (GTTF) for 
electroporation into a custom line of mouse embryonic stem cells.  The targeting 
of the core enhancer for homologous recombination occured on a chromosome 
already lacking the DRR.   The GTTF created a hybrid ESC line by crossing mice 
lacking the DRR, maintained on a 129SvJ background, with 129SvEv mice.  
Blastocysts were collected to create the new ESC line.  The CE targeting vector's 
homology arms come from the 129SvJ strain, with the intended purpose of 
enhanced targeting of the correct chromosome. 
ESC clones were screened for proper recombination via BclI digest and 
Southern blot on the 5’ side.  The southern probe was PCR amplified from 
mouse genomic DNA using the forward primer 5'-GGCGGATCC 
TGAACAAAAGGGGATGAGATTCC-3' and reverse primer 5'-CGCGAATT 
CAGGAACCACCCTAAAGATCCACC-3'.   The resulting fragment was subcloned 
in pBS SK+ plasmid.  
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The 3'  end of the recombination event was assayed by nested long range 
PCR.  The external PCR primer sequences are  5'-AGTAGAAGGTGGC 
GCGAAGG-3' and 5'-TCAAGCCGGCCACCATAAAG-3'.  The internal PCR 
primers are 5'-TCATTCAGGAGAGCCTTTGTT-3' and 5'-TGGATGTGGA 
ATGTGTGCGAG-3'.  The final amplicon is 4.6 kb in length.  The Invitrogen 
Elongase system (cat # 10480-010) was used for long range PCR. 
 
Mouse breeding 
  
 Chimeric mice were received from the UCHC GTTF and selected for 
breeding based on coat color composition as an indication of targeted cell 
contribution to the chimeric mice.  Chimeras were mated with FVB (albino) mice 
in order to generate offspring with colored coats indicative of germline 
transmission.  These pups were genotyped via tail snips, DNA isolation and PCR 
for both the CENeo and DRRloxP alleles.  Successful germline transmission also 
demonstrated if the correct chromosome was targeted such that if both alleles 
travel together , the correct chromosome was targeted. 
 CENeo male mice were crossed with HprtCre females (Jax stock #004302) 
and R26Flpe females(Jax stock #003946) to generate MyoDΔCE15DRR/+ and 
MyoDΔCEDRR/+ mice, respectively.  Offspring harboring the recombined CE locus 
were interbred for expansion of stock animals and for staged collection.  Timed 
matings were set up at night, with noon following the morning of a vaginal plug 
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considered E0.5.  The separate knock out lines were also mated to Myf-5Neo (S. 
Tajbakhsh) mice in order to create double heterozygous mice. 
  
Embryo harvesting and staging 
 
Pregnant female mice were sacrificed following IACUC approved 
protocols.  Mice were anesthetized before cervical dislocation.  The uterus was 
removed and placed into dishes filled with RNAse free PBS.  Individual embryos 
were collected and placed into 2% PFA in PBS overnight at 4oC on a shaker.   
 
PCR analysis of genomic DNA from tail snips and embryo yolk sacs 
 
The yolk sacs from each embryo were placed in 1.5ml tubes followed by 
Proteinase K digestion.   The next day, DNA was purified via diatomaceous earth 
extraction. 
PCR primers used for genotyping: 
MyoDΔCE15DRR forward 5'- CTTGGAACCACACTACCTCAAGG-3' reverse 5'- 
CCAGA TAGATGTCTCCCAGGCTTG-3'  to create 350 bp product 
MyoDΔCEDRR  forward 5'- CTTGGAACCACACTACCTCAAGG-3' 
reverse 5'- GTTCCTCTCATGCCTGGTGTTTAGG-3' to create a 230 bp product 
Myf-5Neo forward 5’-CGTTGGCTACCCGTGATATT-3’ and reverse 5’-  
CAGCTCAGCTTTGTGTGCTC-3’to create a 670bp product. 
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Myf-5 Wild type forward 5'-TGAAGGATGGACATGACGGAC-3' and reverse 5'-
TGACCTTCTTCAGGCGTCTACG-3' to create a 300bp product 
 
DIG-labeled RNA probe creation for in situ hybridization 
 
 The plasmid, mMyoD-MS/BSIIPSK, contains the 3' portion of the MyoD 
cDNA, and was provided by Dr. Masakazu Yamamoto.  The cDNA portion of the 
plasmid was PCR amplified using standard conditions, and used the M13 forward 
and reverse primers.  The PCR product was run on an agarose gel.  The product 
band was cut from the gel and purified, using the Macherey-Nagel NucleoSpin 
Gel and PCR clean-up kit, as per manufacturers instructions (ref # 740609.10).  
The purified product was PCR amplified as previously stated and repurified. 
 Digoxigenin labeled mRNA was created using the purified PCR product as 
the template, with a labeling kit by Roche (cat # 11 277 073 910) and using T3 
and T7 polymerase to generate sense and anti-sense probes.  
 
In situ hybridization for MyoD transcripts 
 
Gentle rocking of embryos occurred during all following incubations.  
Embryos were fixed in 2% paraformaldehyde in PBS at 4°C overnight.  Embryos 
were rinsed and dehydrated in a gradient of methanol mixed with PBT (PBS with 
0.1% Tween) (25%, 50%, 75% and 100% methanol) for 10 minutes each.  
Embryos were stored at -20°C in 100% methanol until needed.  Embryos were 
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returned to room temperature and rehydrated in a reverse gradient in methanol 
and PBT.  For better probe penetration, embryos were digested in 10µg/ml 
ProteinaseK/PBT for 20 minutes, rinsed in PBT, then fixed in 0.2% 
glutaraldehyde/4% paraformaldehyde/PBT for 20 minutes.  Following rinses in 
PBT, embryos were incubated in a 1:1 mix of PBT and prehybridization buffer, 
followed by 100% prehybridization buffer for over 1 hour (minimum 2 hours 
yielded best results) at 70°C.  The prehybridization buffer is composed of 50% 
formimide, 5xSSC, 2%SDS, 2% Roche Blocking Reagent (cat#11096176001), 
250µg/ml yeast tRNA, 100µg/ml heparin, in RNase free H2O.  Digoxygenin 
labeled RNA probe was then added to a concentration of .25µg/ml and incubated 
at 70°C overnight. 
Embryos were washed in SolutionX ( 50% formamide, 2XSSC, 1% SDS) 5 
times, 20 minutes per wash, at 70°C.  Embryos were then incubated for 20 
minutes as 70°C in a 1:1 mix of SolutionX and MABT (for 50ml of MABT mix .29g 
maleic acid, .218g NaCl, .5ml 10% Tween20, and H20 to make 50 ml and 
adjusted pH to 7.5 with NaOH).  Embryos were then washed 4 times at 5 minutes 
per wash in MABT at room temperature.   
 Embryos are incubated in 2% Roche Blocking Reagent (cat 
#11096176001) in MABT for 30 minutes at room temperature.  Continue with a 
two hour room temperature block in 2% Roche Blocking Reagent/20% Fetal 
Bovine Serum in MABT.  Anti-Digoxygenin-AP Fab were then added to a 1:2000 
dilution and incubated at least 1 overnight (2 overnights gives best result) at 4°C. 
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Following incubation with the anti-DIG antibody, embryos were washed 
four times, at 1 hour per wash in MABT,  followed by an overnight wash in MABT, 
all at room temperature. 
Wash embryos in NTMT (100mM NaCl, 100mM TrisCl pH 9.5, 20mM 
MgCl2, 0.2% Tween 20) three times, ten minutes per wash at room temperature.  
Replace NTMT with BM Purple (cat #11442074001) and develop color to 
appropriate level, usually 6-8 hours.  After color development level is reached, 
rinse embryos in NTMT several times to minimize precipitate formation, then 
continue rinsing in PBT. 
 
Embryo imaging 
 
 Whole mount images were taken using a Lecia MZ FLIII.  Images were 
captured using a Spot 25.2 2 Mp Color Mosaic camera using Spot Software V4.6 
by Diagnostic Instruments.  Images were modified using Photoshop CS2.  
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3.4 Results: 
 
 
3.4.1 Targeting the Core Enhancer for deletion: 
 
 
 To define the compensatory abilities of the CE and DRR or to provide data 
that uncharacterized enhancers exist, the CE was targeted for deletion in 
mouse embryonic stem cells (ESCs) already lacking the DRR.   ESCs were 
created by the UCHC through mating male DRRloxP male mice, maintained on a 
129SvJ genetic background, to the cell culture friendly strain, 129SvEv.  
Blastocysts created form the mating were collected to create the new ESC line.  
The targeting vector, p5’FLNeoLF3’tk, was created to precisely replace the 
258bp CE with a Neomycin resistance gene, flanked by loxP sites, all of which 
was flanked by FRT sites (Fig 3-1A).  The presence of two different 
recombinase targets allows for creation of two different lines from the same 
targeting event, described below.  The homology arms of the targeting vector 
originated from the 129SvJ strain to increase efficiency of targeting the correct 
chromosome by sequence similarity.  Homologous recombination was assayed 
by southern blot on the 5' side and long range nested PCR on the 3' side (Fig. 
3-1B and C).   
Following germline transmission of the targeted locus, male offspring 
were mated with both R26Flp and HprtCre females to produce two different lines 
via recombination.  Flippase dependent recombination (Schaft et al., 2001) 
removes the floxed Neo cassette, leaving a transcriptionally inert FRT site, 
creating the new line lacking both the CE and DRR, MyoDΔCEDRR/+ .  Cre 
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recombination (Nagy, 2000) of the MyoDCENeo allele when located on a DRRloxP 
chromosome, results in removal of the 15kb of DNA from the 5’ end of the Neo 
cassette to the 3’ end of the former site of the DRR, called MyoDΔCE15DRR/+ (Fig 
3-2A and B).  The new lines were expanded by mating with FVB mice.  
Heterozygous and homozygous mutant mice were all equally viable.   
 
3.4.2 MyoD mRNA expression in MyoDΔCEDRR/ΔCEDRR embryos  
 
 In order to observe the effect on MyoD expression patterns when both 
known enhancer elements were removed, MyoDΔCEDRR/+  mice were intercrossed, 
and embryos from pregnant females were collected between E9.5 and E12.5.  
Noon following the morning of vaginal plug detection was considered E0.5 for 
staging purposes.   Whole mount in situ hybridization was performed to visualize 
MyoD transcripts.  Successful validation of the probe and the sense control probe, 
a sequence that is identical to MyoD mRNA and should not produce a specific 
signal is shown in Fig 3-3. 
 Comparisons between wild type and heterozygous embryos show no 
phenotypic difference, meaning haploinsufficiency is not an issue and allows for 
heterozygous embryos to be used as a reference point in some figures (Fig 3-4). 
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Figure 3-1.  Targeting the Core Enhancer for deletion 
 
The 258bp Core Enhancer lies approximately 22 kb upsteam of the MyoD locus 
and was targeted for precise removal by the targeting vector, p5’FLneoLF3’tk.  
The targeting vector contains a 3.7kb 5’ homology arm, ending at the EcoRI site  
5’ of the CE, and a 3.6kb 3’ homology arm, that ends at the XhoI site 3’ of the CE.   
After homologous recombination, the CE is replaced by a PGKNeo cassette 
flanked by loxP and FRT sites, in reverse orientation in respect to the 
transcriptional orientation of MyoD.  Desired recombination on the 3’ side was 
assessed via long range nested PCR, where 3 of the four lanes show the 
targeted 10kb band size along with the wild type 8.5kb band (Fig 3-1B). 
Detection of proper recombination was carried out on the 5’ end by BclI digest 
and southern blot using the DNA probe depicted.  Fig. 3-1C shows correctly 
targeted clones in lanes 2, 4 and 5.   
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Figure 3-2.  Creation of MyoDΔCEDRR and MyoDΔCE15DRR mice 
 
Following germline transmission of the CENeo allele, two different recombination 
events need to take place to create the two new mutant lines.  CENeo male mice 
were mated with R26Flpe female mice to recombine out the PGKNeo cassette, 
creating the MyoDΔCEDRR/+ line (Fig 3-2A).  Appropriate recombination was 
assessed via PCR using primers F1 and R1, that generate a 210 bp band if 
recombination took place, while non recombinant alleles would generate an 
approximate 430bp fragment. 
CENeo male mice crossed with HprtCre females to produce the MyoDΔCE15DRR/+  
line.  Proper recombination was assessed via PCR using primers F2 and R2, to 
create a 350bp product if recombination took place, and no product if 
recombination did not take place as the primers lie approximately 15kb away 
from each other in the genome.   
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Figure 3-3. Validation of MyoD in situ probe 
 
E12.5 littermate embryos hybridized with either the sense or anti-sense RNA 
probe to detect endogenous MyoD mRNA.  The antisense probe complimentary 
base-pairs with MyoD transcripts and produces the expected signal profile.  The 
sense probe RNA sequence is identical to MyoD transcripts and serves as a 
control against non specific binding of the anti-sense probe or hybridization to 
genomic DNA.  Note the lack of and real signal, with only minor background, in 
the sense probe panel. 
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Figure 3-4 
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Figure 3-4. MyoDΔCE15DRR heterozygote and Wild Type MyoD mRNA profiles 
 
In situ hybridization for MyoD transcripts of heterozygous MyoDΔCE15DRR/+  
embryos was compared to wild type embryos to asses any haploinsufficiency.  
E10.5 (A and B) and E12.5 (C and D) embryos showed no significant differences 
in timing or intensity of expression between heterozygous and wild type embryos.  
In panels A and B, the yellow arrows indicate the forelimb buds and the green 
arrows indicate the hindlimb buds.  In panels C and D, the red arrows indicate 
the branchial arches. 
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 A comparison of MyoDΔCEDRR/ΔCEDRR and wild type embryos between E9.5 
and E12.5 shows that the CE and DRR are not the only enhancers of MyoD and 
they do not compensate for each other when one is absent.  Generally, the 
phenotype in MyoDΔCEDRR/ΔCEDRR  embryos is a combination of CEloxP and 
DRRloxP single knock out phenotypes, described previously (Chen et al., 2002) 
(Chen and Goldhamer, 2004b).  At the onset of MyoD expression in the myotome 
and branchial arches at E9.5, MyoD expression is absent in both areas in the 
mutant embryos (compare Fig 3-5A to 3-5E).  The lack of early myotomal 
expression is the only significant phenotypic difference between 
MyoDΔCEDRR/ΔCEDRR  mutant embryos and either CEloxP or DRRloxP single mutants.  
In either single knock out, the timing of myotomal MyoD expression is identical to 
wild type embryos (Chen et al., 2002; Chen and Goldhamer, 2004b).  It can now 
be said that timely activation of myotomal MyoD expression is dependent on 
either the CE or DRR being present.  By E10.5, the epaxial signal has largely 
recovered, with only a mild reduction in signal intensity in the mutant embryos 
similar to DRRloxP embryos.  The hypaxial lineage that gives rise to muscle beds 
in the limb buds and branchial arches still exhibits a pronounced delay, with no 
signal in limb buds of MyoDΔCEDRR/ΔCEDRR embryos at E10.5(Fig 3-5 B and F).  At 
E11.5, MyoD expression is largely identical between wild type and mutant 
embryos, with a slight delay in hindlimb expression in the mutants (Fig 3-5 C, G).  
The expression profile of MyoD eventually recovers in mutant embryos by E12.5 
(Fig 3-5 D and H) and is nearly indistinguishable to wild type embryos. 
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Figure 3-5. Timeline of MyoD expression in MyoDΔCEDRR/ΔCEDRR  and wild 
type embryos 
 
Whole-mount in situ hybridization for MyoD mRNA in WT embryos (A-D) and 
litter mate MyoDΔCEDRR/ΔCEDRR embryos (E-H).  At E9.5, (A and E) branchial arch 
expression is present in the wild type embryo and absent in the mutant,  as seen 
in the magnified areas (red boxes).  Red arrows indicate early myotome 
expression in the wild type embryo (A) that is absent in the mutant embryo (E). 
At E10.5, branchial arch expression (yellow arrow) still lags in mutants. Forelimb 
signal (green arrows) is present in wild type (B) embryos and lacking in mutant 
embryos (F).  E11.5 forelimb expression is similar between (C) and (G), while 
hindlimb expression, red arrows, still lags in the mutant.  By E12.5, (D and H) 
embryos have nearly identical expression patterns, although the expression level 
is slightly reduced in the mutant. 
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3.4.3 Pax-3 dependent rescue of MyoD expression is independent of the CE 
and DRR 
 
In the absence of Myf-5, MyoD expression is delayed  in the myotome by 
approximately 2 days, with no effect on the hypaxial lineages (Tajbakhsh et al., 
1997).   The factor that rescues MyoD expression in Myf-5 mutants is Pax3.  In 
the absence of Pax3, limb myogenesis fails, as myogenic progenitors can’t 
migrate from the somite to the limb due lack of activation of downstream target 
genes, such as c-met (Bober et al., 1994b) (Daston et al., 1996a).  Embryos 
lacking both Myf-5 and Pax3 fail to activate MyoD in the body, due to the 
dependence of either gene to activate transcription of MyoD.  MyoDΔCEDRR/+;Myf-
5Neo/+ mice were intercrossed to create MyoDΔCEDRR/ΔCEDRR;Myf-5Neo/Neo embryos 
in order to determine if the CE and DRR are the only elements responsive to 
Pax3 dependent activation.  E11.25 embryos lacking only Myf-5 exhibit the early 
stages of Pax3 dependent myotomal MyoD expression (Figure 3-6 A,B).     In 
MyoDΔCEDRR/ΔCEDRR;Myf-5Neo/Neo embryos at this stage,  myotomal expression is 
nearly identical to Myf-5Neo/Neo embryos. The delay observed in limb expression is 
due only to the absence of the CE and DRR.  By E12.5 (Figure 3-6 C-E), Pax3 
dependent MyoD rescue is complete, even with the absence of known MyoD 
enhancers. 
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3.4.4 The 15kb of DNA between the CE and DRR is not involved in 
embryonic transcription of MyoD or in Pax3 dependent expression 
 
 The results from the discrete enhancer knock outs show that at least one 
other enhancer exists.  This was a possible result, so the targeting vector was 
designed to allow for precise removal of the CE and DRR, but also for removal of 
the genomic sequence between the CE and DRR. 
In the new line, called MyoDΔCE15DRR, both the CE and DRR are absent, 
along with the intervening DNA.  The expression profile of homozygous embryos 
is identical to the that of embryos lacking only the CE and DRR (compare Figures 
3-5 to 3-7).  The delay and eventual recovery of MyoD expression in the hypaxial 
lineage mirrors that of MyoDΔCEDRR/ΔCEDRR embryos. 
 We also investigated whether Pax3 dependent rescue of MyoD 
expression occurs though the sequence between the CE and DRR.  Figure 3-8 
shows the same delay and rescue kinetics of MyoD expression exists in 
MyoDΔCE15DRR/ΔCE15DRR;Myf-5Neo/Neo as in Myf-5Neo/Neo embryos. 
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Figure 3-6. Removal of the CE and DRR does not affect Pax3 dependent 
rescue of MyoD expression 
 
At E11.25 (A-C) early rescue of myotomal MyoD expression is underway in       
Myf-5Neo/Neo and MyoDΔCEDRR/ΔCEDRR;Myf5Neo/Neo embryos (red arrows).  Delay of 
MyoD expression in limb buds and branchial arches is due to the lack of the CE 
and DRR, and does not reflect the absence of Myf-5.  By E12.5 (D-F), the 
myotomal expression of MyoD is similar between MyoDΔCEDRR/ΔCEDRR;Myf5Neo/Neo 
and Myf5Neo/Neo embryos.  The aberration in expression in the trunk is due to the 
rib defect seen in Myf-5Neo/Neo only embryos (compare D and E, red arrows). 
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Figure 3-7 
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Figure 3-7. Whole mount in situ hybridization for MyoD mRNA in 
MyoDΔCE15DRR/ΔCE15DRR  and wild type embryos 
 
Wild type embryos (A-D) are compared to MyoDΔCE15DRR/ΔCE15DRR embryos (E-H).  
Red panels in A and D indicate zoomed in areas showing either a presence or 
absence of MyoD signal in the branchial arches.  In B and E, branchial arch 
staining (yellow arrows) is present in the mutant embryo, but is not as advanced 
as the wild type embryo.  Green arrows show the delayed activation of MyoD in 
the forelimb buds.  By E11.5, (C and G), mutant embryos largely mimic the wild 
type expression pattern.  There is less expression in the hindlimbs (red arrow) in 
mutants than in wild type embryos.  At E12.5 (D and H), expression is similar in 
both embryos. 
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Figure 3-8 
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Figure 3-8. Pax3 dependent  MyoD expression occurs normally in 
MyoDΔCE15DRR/ΔCE15DRR embryos 
 
At E11.25 (A-C) early myotomal MyoD expression in MyoDΔCE15DRR/ΔCE15DRR 
embryos is identical to embryos with or without the CE and DRR.  Limb bud 
expression differences (B and C versus A) result from the absence of the CE, 
DRR and intervening sequence.   Myotomal expression, dependent on Pax3 
(compare B and C) are identical (red arrows).  At E12.5, myotomal MyoD 
expression is nearly identical between MyoDΔCE15DRR/ΔCE15DRR and wild type 
embryos(D-F).  The only difference in myotomal expression is due to the Myf-
5Neo/Neo  genotype (red arrows) that causes rib defects involving intercostal 
muscles. 
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3.4.5 Genome Database Analysis 
 
 The lack of dramatic phenotypes in MyoDΔCEDRR/ΔCEDRR and 
MyoDΔCE15DRR/ΔCE15DRR embryos led us to search for enhancer regions using 
database analysis.  Two million bases, centered on the MyoD locus, were 
analyzed for conservation of DNA sequence among mammals (rat, dog, human, 
orangutan, and horse), a marsupial (opossum), the chicken, and the stickleback 
fish.  Active chromatin markers from C2C12 myoblasts were also considered in 
the search for enhancer elements. 
 The Genome Browser, created at The University of California, Santa Cruz, 
allows for integration of genome data from various groups.  We looked for 
sequence conservation across a number of species, as this is a strong indicator 
of important sequences.  The CE and DRR were known to be conserved 
between humans and mice, and they are highly conserved among most 
mammals analyzed (Figure 3-10 A and B).  Included in the analysis was the level 
of mono-, di-, and tri-methylation of the protein tail of histone 3, lysine 4 (H3K4) in 
the C2C12 cell line.  This specific epigenetic marking is indicative of active 
chromatin, and forced methylation of H3K4 leads to gene activation (Snowden et 
al., 2002; Towbin et al., 2012).  H3K4 methylation is also a strong epigenetic 
indicator of enhancers (Bernstein et al., 2006).  Specifically, H3K4 di and tri-
methylation have been proven to mark active enhancers (Pekowska et al., 2011).  
Using a myoblast cell line gives more relevant data about portions of the genome 
available for transcription factor binding, and thus transcriptional control.  
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 In the 2 million bases flanking MyoD, we found no evolutionarily 
conserved sequences that were also highly methylated outside of protein coding 
genes.   Some of the conserved genes have active histone modifications, while 
many did not.  The heavily methylated, conserved genes, such as Emp3, and 
Gys1, are both expressed in muscle cells.   Emp3 is involved in cell proliferation 
and Gys1 encodes a metabolic gene, glycogen synthase (Villarroel-Espíndola et 
al., 2013).  The locally non-methylated, conserved genes encode proteins 
involved in various non-myogenic organ systems, such as Otog, a gene involved 
in inner ear development (Schraders et al., 2012). 
 Sequence conservation in non-protein coding regions of the genome 
indicates important regions that can contain regulatory elements.  The four MRFs 
likely arose from gene duplication and divergence during evolutionary history 
(Dermitzakis and Clark, 2001).  Myf-5 has high sequence and functional similarity 
to MyoD, and Myf-5 has important enhancers in its introns (Carvajal et al., 2001).  
The idea that intronic enhancers may exist for MyoD is supported by unpublished 
observations by Masakazu Yamamoto.  In a targeted mutation creating a new 
MyoD allele, the exons and two introns of MyoD are flanked by loxP sites, 
followed by the GFP gene.  Following Cre recombination, the MyoD gene is 
removed, and GFP should be driven by the local enhancers.  However, GFP 
expression does not occur in myogenic regions of the embryo, perhaps due to 
the removal of intronic enhancers.  The MyoDiCre allele, used in the previous 
chapter, shows robust activity in myogenic cells.  However, this allele only 
removes exon 1 and the first 42 nucleotides of intron 1 (Kanisicak et al., 2009).  
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Interestingly, sequence analysis of MyoD shows the highest levels of H3K4 tri-
methylation occurring in intron 1.  There are also several short regions in intron 1 
that are evolutionarily conserved across several mammalian species (Fig 3-9).   
 Intronic sequences were compared for any similarity between MyoD and 
Myf-5, and no significant similarities were found (data not shown).  However, 
transcription factor binding sites, based on sequence only, are plentiful in intron 1 
of MyoD, and many of these motifs are present in intron 2 
(http://jaspar.genereg.net/).  Binding sites of interest include Klf4, Sp1, En1, Ap1, 
Pax2,  Sox 5, 10, and 17.  Klf4 is an indicator of stem cell like capacity in hESC 
cultures and is used in formation of induced pluripotent stem (iPS) cells 
(Tahmasebi et al.).  Sp1 is known to regulate expression of many genes involved 
in cell proliferation, apoptosis, and differentiation (Chu, 2012).  En1, or engrailed, 
is a homeobox containing transcription factor involved in dorso-ventral patterning 
of the limb field during embryogenesis (Hanks et al., 1998).  Ap1 controls cell 
division and  cell death decisions (Alani et al., 1991) and is known to work with 
Pax2, another vital factor in embryogenesis (Zhang et al., 2012).   Sox 5 plays a 
role in differentiation during embryogenesis and Sox 17 works to inhibit Wnt3a 
singaling (Vervoort et al., 2012).  The computational data indicates that putative 
binding elements for relevant factors exist within the introns of MyoD and warrant 
further study.   
 The lack of positive epigenetic modifications, and presence of negative 
epigenetic changes were also examined in non-myogenic cell types.   H3K4 
methylation is absent in neural, heart, and liver tissue, as well as erythroblasts 
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and  megakaryocytes.  In fact, all non-myogenic cell types exhibited high levels 
of transcriptionally repressive marks, such as H3K27 and H3K9 tri-methylation 
(Barski et al., 2007).  A marker of active chromatin is acetylation of lysine in H3.  
C2C12 cells contain H3K9ac, while all other cells types analyzed, including, brain, 
liver,  and heart tissue, lacked this positive epigenetic mark. 
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Figure 3-9 
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Figure 3-9. Database analysis of the MyoD locus reveals sequence 
conservation across species and positive epigenetic markings 
 
Data obtained from the University of California, Santa Cruz, Genome Browser.  
Analysis of the genomic sequence surrounding the MyoD locus includes 
sequence conservation across species along with active histone modifications in 
the C2C12 immortal myoblast cell line.   Abbreviations: (STS) sequence tagged 
site,  (EST) expressed sequence tag, (H3K4me3) histone 3, lysine 4, tri-
methylation.  The MyoD coding region shows high sequence similarity across 
species in exons, with high levels of H3K4me3 in introns 1 and 2.  Intron 1 also 
shows sequence conservation across several species. 
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Figure 3-10. Database analysis of the CE and DRR reveals high sequence 
similarity across species 
 
Sequence images of the murine CE (A) and DRR (B).  The discrete enhancer 
areas are boxed in red.  Sequence conservation is high across species and is 
higher than outside of the boxed regions.   
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3.5 Discussion: 
 
When the 24 kb of human sequence upstream of MyoD is attached to 
either GFP or lacZ and placed in the mouse genome, reporter gene expression 
almost flawlessly mimics endogenous MyoD expression (Chen et al., 2001).  
Other transgenic experiments demonstrated distinct functions between the two 
known MyoD enhancers contained in the 24kb of sequence.  The CE transgene 
showed activity concurrent with initiation of MyoD expression, and the DRR was 
active in differentiating muscle (Chen et al., 2001).  When either of the discrete 
enhancers were eliminated from the mouse genome, only slight defects occurred,  
leading to the hypothesis that the enhancers could compensate for each other 
when one was absent (Chen et al., 2002; Chen and Goldhamer, 2004b).  In this 
present study, we have shown that at least one other uncharacterized enhancer 
exists, and that they are largely responsible for the proper spatio-temporal 
transcription profile of MyoD during embryogenesis.  This study is a striking 
example of necessity versus sufficiency.  The known enhancers are sufficient to 
drive reporter gene expression in a pattern that mimics MyoD, but none of the 
known enhancers are necessary for it.   
Recent studies regarding upstream regulators of MyoD show pronounced 
muscular defects after eliminating trans acting regulators that have been shown 
to bind the CE or DRR.  Positive regulators, such as YB1/p32 (Song and Lee, 
2010), Six1/4 and Eya1/2 (Grifone et al., 2005), BMAL1/Clock (Andrews et al., 
2010) (Zhang et al., 2011), Pitx2 (L'Honore et al., 2010), and the transcriptional 
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repressor Sim2 (Metz et al. 2006, Havis et al. 2012) have demonstrable effects 
on MyoD transcription.  Although binding of these various factors to the CE have 
been shown in vitro, the CE may not be the only target, and the introns or other 
DNA elements may be binding sites for these factors.  It should be noted that 
some of the previous studies examined postnatal transcriptional control, and that 
aspect of myogenesis has not been addressed in this study.  The CE's function 
may be to  control the circadian oscillation of MyoD expression in adult muscle, 
via binding of CLOCK1/BAML to the CE, however, only the CE and 6kbs of DNA 
upstream of MyoD were assayed for binding (Andrews et al., 2010).  In mice 
lacking only the CE, CEloxP/loxP, MyoD expression oscillation is only dampened, 
not eliminated (Zhang et al., 2011).  In all studies mentioned above, it may be 
that DNA elements outside of the CE and DRR are involved as well.   
 In this study, it has been shown that in the absence of both the CE and 
DRR, MyoD expression is largely unperturbed, with only a delay in MyoD 
expression in the limb buds and branchial arches.  This phenotype was also 
observed when only the CE is removed (Chen and Goldhamer, 2004b).  
MyoDΔCE15DRR/ΔCE15DRR embryos displayed MyoD expression identical to the 
pattern in MyoDΔCEDRR/ΔCEDRR embryos.  This result is not unexpected, as there 
have been no studies implicating the sequence between the CE and DRR as a 
potent regulator of MyoD expression.  Now there is definitive proof that no 
necessary regulation of MyoD occurs via this DNA sequence.  There is a portion 
of F3 that remains in MyoDΔCE15DRR/ΔCE15DRR  animals that may have regulatory 
abilities.  The CE was found to be the most potent portion of F3, but the 
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approximately 1.5 kb of F3 that remains could partly control transcription 
(Goldhamer et al., 1995).   
 The targets of the Pax3 dependent rescue pathway of MyoD expression in 
the absence of Myf-5 was investigated in our two now mouse lines.  We have 
shown that the rescue kinetics are similar between wild type embryos and both 
MyoDΔCEDRR/ΔCEDRR and MyoDΔCE15DRR/ΔCE15DRR embryos.  These results are 
striking when compared to numerous transgenic analyses.  In a fine scale 
transgenic mapping study of the CE, where only the CE and proximal promoter of 
MyoD controll lacZ expression, 15 bases of the CE were replaced with a linker 
sequence at a time.  Two adjacent sequences, when mutated, both resulted in 
the loss of reporter expression in the myotome and myotome derived muscles.  
(Kucharczuk et al., 1999) This mutated construct showed no activity in the trunk 
of Myf-5 null embryos, showing the exact portion of the CE that is a target of 
Pax3 rescue (Chen and Goldhamer, 2004a), albeit not the only target.   
 There remains the possibility of regulatory element in the 2kb upstream of 
the CE.  Transgenic studies using 24kb of human DNA upstream of MyoD, with a 
4kb fragment removed, to drive lacZ expression exhibited reporter gene 
expression delay throughout the embryo (Chen et al., 2001).  Importantly, near 
the center of this 4kb deleted fragment lies the CE.  Both the MyoDΔCEDRR/ΔCEDRR 
and MyoDΔCE15DRR/ΔCED15RR lines retain the 2 kb portion.  Database analysis 
shows the 2 kbs directly upstream of the CE contain a similar amount of H3K4 tri-
methylation as the CE itself, but the amount of sequence conservation between 
species is  higher in the 258 bps of the CE (Figure 3-10A). 
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  Database analysis supports the hypothesis that enhancers exist in the 
introns of MyoD, particularly in intron 1.  Sequence analysis of the MyoD shows 
that of all the surrounding sequence analyzed, the highest levels of H3K4 tri-
methylation, an epigenetic marker of enhancers,  occurs in the introns.  There is 
also a short region in intron 1 that is evolutionarily conserved across several 
mammalian species and contains multiple, unproven, transcription factor binding 
sites.  These active chromatin modifications are not present in non-muscle cell 
types.  In non-muscle cell types, the entire MyoD locus contains repressive 
chromatin modifications, such as H3K9 and K3K27 tri-methylation.  A follow up 
experiment is warranted to address intronic enhancers.  Either a transgenic study 
where the introns drive reporter gene expression, or targeting the MyoD locus to 
replace the entirety of MyoD with a reporter gene can be performed.     
 The intricate pattern and timing of MyoD expression throughout the entire 
embryo implies a more complex regulatory system than currently known.  The 
regulatory network of the conserved family members, Myf-5 and Mrf4, has 
proven to be quite complex, and this study indicates that MyoD may have 
similarly complex regulation.  Myf-5 enhancer elements span over 140kb and 
there are distinct roles for each of the 19 enhancers identified in location of 
expression, timing of expression, or both (Buchberger et al., 2003; Carvajal et al., 
2001; Hadchouel et al., 2003; Summerbell et al., 2000).  Also known is that some 
enhancers of Myf-5 are contained in the introns (Carvajal et al., 2008).  The 
signaling environments that lead to MyoD expression are different at the three 
main areas of embryonic myogenesis, namely,  the head, trunk and limbs 
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(Moncaut et al., 2013).    This variability in regulatory factor environments implies 
multiple enhancers and is consistent with the findings presented here, as we 
demonstrated that the embryonic transcriptional regulation of MyoD is more 
complex than previously shown.   
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Chapter 4  MyoD lineage ablation and the role of myogenesis in proper rib 
development 
 
4.1 Abstract: 
 
In order to address the mode of redundancy between MyoD and Myf-5, we used 
the MyoDiCre allele to activate the Cre dependent diphtheria toxin (R26DTA) gene 
resulting in the death of any cell that activates the MyoD locus  Preliminary data 
at E18.5 shows the complete absence of skeletal muscle, evidenced by a lack of 
Myosin Heavy Chain expressing cells.  This result is in contrast to previously 
reported Myf-5Cre;R26DTA embryos, where myogenesis occurs and embryos are 
born with functional muscle, indicating that all myogenic cells express MyoD, but 
not Myf-5, during development.  Interestingly, there was an unexpected rib 
malformation phenotype in MyoDiCre;R26DTA embryos.  This observation led to 
analysis of the dependency of rib development on appropriate muscle formation 
in the myotome. We examined the rib malformation phenotype in Myf-
5loxP/loxP;MyoDiCre/Neo, Myf-5Neo/Neo;MyoDiCre/Neo and MyoDiCre/+;R26DTA embryos, 
three genotypes known to affect myotome formation and development at different 
times.  It appears that normal rib development requires the timely formation of 
the myotome, as well as continued presence of intercostal muscles, such that the 
earlier the perturbation in myotome formation and development, the more severe 
the rib defect. 
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4.2 Introduction: 
 
Lineage Ablation 
 
 Since the seminal research regarding the genetic control of embryonic 
myogenesis, there has been an open question regarding the mode of 
redundancy between MyoD and Myf-5.  These transcription factors are largely 
similar in DNA sequence, and share an identical DNA binding domain.  When 
either MyoD or Myf-5 is deleted from the mouse genome, myogenesis occurs 
almost normally, and embryos are born with functional skeletal muscle (Braun et 
al., 1992; Rudnicki et al., 1992a).  However, when both genes are deleted, no 
skeletal muscle forms in the embryo. (Rudnicki et al., 1993).   The question 
became, are MyoD and Myf-5 functionally redundant in the same cells, or are 
there redundant lineages, ie a MyoD dependent and a Myf-5 dependent lineage?  
 Recently, the two separate lineage hypothesis was supported by the 
diphtheria toxin (DTA) induced cell death after activation of the Myf-5 locus 
(Gensch et al., 2008; Haldar et al., 2008).  The Cre gene was knocked into the 
Myf-5 locus, where  activation results in cre-mediated recombination of R26DTA, 
and diphtheria toxin production, causing cell death by inhibiting protein 
translation via elongation factor 2 (Ivanova et al., 2005; Pappenheimer, 1977).  
Skeletal myogenesis still occurs in these embryos, via a Myf-5 independent 
lineage. 
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 Putting lineage ablation under the control of the MyoD locus was 
performed using MyoDiCre/+;R26DTA embryos and results in the lack of skeletal 
muscle at E18.5.  This preliminary data shows that all cells of the myogenic 
lineage activate the MyoD locus.  
 
Rib Development 
 
 The original Myf-5 knockout allele, Myf-5Neo, resulted in severe, perinatal 
lethal,  rib defects (Braun et al., 1992).  However, MyoDNeo/Neo embryos did not 
exhibit a rib phenotype (Rudnicki et al., 1992b).  Thought only to control 
myogenesis, the connection between the allele, and the unexpected rib 
phenotype was a major point of interest.  The Myf-5Neo allele retains the PGKNeo 
selection cassette, and it was hypothesized that the disrupted allele affected 
expression of other unspecified genes involved in rib development.  After a more 
discrete allele was created, Myf-5loxP, it was found that the rib defect was 
eliminated.  The Neo cassette was transcriptionally silencing the physically close 
myogenic gene, Mrf4 (Kassar-Duchossoy et al., 2004).  Myf-5 and Mrf4 control 
the formation of the myotome, and MyoD plays a later role in myotomal 
development. 
 Generally, functional muscle aids in proper embryonic bone growth by 
providing static load and contractions to stimulate osteogenesis (Hamrick, 2010).  
Aside from the rib truncation phenotype, MyoD-/-;Myf-5Neo/Neo embryos have fused 
vertebra, malformed mandibles and palate (Rot-Nikcevic et al., 2006), and close 
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proximity of the radius and ulna (presented in Chapter 2).  The rib phenotype 
appears to be caused by much earlier stages in myogenesis, prior to functionally 
contractile muscle formation.  The close proximity of the developing axial 
skeleton, arising from the sclerotome, and the myotome, may point to a signaling 
pathway between the two, such that the lack of a myotome perturbs signaling 
and results in a malformed rib cage.  It has been found that the myotome allows 
for PDGFA and FGF expression in the sclerotome, and that this activation is 
needed to promote rib development (Tallquist et al., 2000; Vinagre et al., 2010).  
In embryos with compromised muscle differentiation, rib development is still 
affected.  When embryos lack Mrf4 and have hypomorphic alleles of Myogenin, 
fusion of ribs to the sternum fails, and the ribs are shaped improperly (Vivian et 
al., 2000).  These two genes are not expressed in axial bones nor the early 
myotome, meaning the resulting rib phenotype is dependent only on the failure of 
myogenic differentiation.   
 Here we report that a link between myotome formation and maintenance 
impacts the extent of rib development, further strengthening the link between  
skeletal muscle and bone development. 
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4.3 Materials and Methods: 
 
Mouse breeding and genotyping 
 
 All mouse handling, breeding, and sacrificing were done in accordance 
with our IACUC animal care protocol. All separate lines were maintained by 
breeding to FVB mice.  Cre dependent DTA expressing mice, R26DTA, were 
obtained from Jaxson Labs (ID #006631) and expanded through intercrossing.  
Offspring were crossed to MyoDiCre/+ animals.  Timed matings were set up by 
taking the morning of vaginal plug as embryonic day 0.5 or E0.5. The MyoDiCre 
allele was detected by PCR using a forward primer (5′-GCGGATCCGAATTC 
GAAGTTCC-3′) that lies at the 3′ end of the icre/+2pA cassette and a reverse 
primer in intron 1 of MyoD  (5′-TGGGTCTCCAAAGCGACTCC-3′), generating a 
product of 149 bp.  No genotyping was required for the DTA allele, as mice 
received were homozygous and the presence of the allele in embryos is evident 
based on EGFP expression in the non-recombined allele.  The MyoDNeo allele 
was detected with the forward primer 5’- TGGATGTGGAATGTGTGCGAG-3’ and 
the reverse primer 5’- TCACTGTAGTAGGCGGTGTCGTAG-3’ to create a 420 
bp product.  The Myf-5Neo allele was detected using the primers 5’-CGTTGG 
CTACCCGTGATATT-3’ and 5’-  CAGCTCAGCTTTGTGTGCTC-3’ creating a 
410 bp product.  Myf-5loxP was detected using the primers 5'- GGTGTCT 
CCTCTCTGCTGAATCCAGGTAT-3' and 5'-AGGTGCACGCACGTGCTCA 
CTGTCTGA-3' to create a 349 bp band.  
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Cryostat sectioning 
 
 Embryos were isolated and fixed with 4% paraformaldehyde for 3.5 hours 
at 4oC. The embryos were rinsed with 4oC PBS 4 times for 20 minutes each. The 
fixed muscle was processed through a sucrose gradient of 15% sucrose in PBS 
overnight, followed by 30% sucrose in PBS overnight all at 4oC . The processed 
tissue was placed into OCT compound and quickly frozen in dry ice cooled 
isopentane. The frozen tissue was cryosectioned at 10 μm and either stored at -
80oC, or immediately processed for observation. 
 
Immunofluorescence 
 
 Skeletal muscle was detected using a mouse anti-Myosin antibody at a 
1:250 dilution (Millipore # MAB1628) and a secondary goat anti-mouse red 
fluorescent antibody 1:500 dilution (Invitrogen # A-21422).  Vector labs MOM kit 
(# BMK-2202) was used as per manufacturers instructions after antigen retrieval.  
The retrieval process entails a 6 min. soak in  -20oC methanol, followed by a 30 
minute incubation in 95oC 10mM sodium citrate pH 6.  A standard block (1% 
BSA, 10% goat serum, 0.1% Tween in PBS) was performed for 2 hours at room 
temperature, followed by a 2 hour primary antibody incubation, also at room 
temperature. 
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4.4 Results: 
 
 Embryonic day 18.5 MyoDiCre/+;R26DTA embryos were collected as an end 
point assay to determine the size of the MyoD expressing lineage.  At this stage, 
there was no muscle visible.  The gross appearance of the embryos (Fig 4-2) 
was similar to the amyogenic embryos in Chapter 2.  Sectioning of the embryos 
followed by antibody detection of myosin heavy chain, a muscle specific marker, 
revealed a complete lack of skeletal muscle in the embryo (Fig 4-1) 
   The rib defect phenotype seen in MyoDiCre/+;R26DTA embryos was not as 
severe as in Myf-5Neo/Neo;MyoDiCre/Neo embryos.  Myf-5Neo/Neo;MyoDiCre/Neo 
embryos also have a transcriptionally repressed Mrf4 gene, and in the absence 
of primary myogenesis, no muscle forms and only rib rudiments or 'nubs' are 
formed (Figure 4-2 A red arrow).   In MyoDiCre/+;R26DTA embryos, early myotome 
development occurs normally.  Early myotome formation is under the control of 
Myf-5 and Mrf4 as they are turned on at E9, while MyoD is not turned on robustly 
until E10.  Cell death does not occur instantly, as Cre must be produced, the 
R26DTA locus must be recombined and produce the toxin to kill the cell, which 
takes at least 24 hours (Saito et al., 2001).  This window of  myogenesis allowed 
for rib outgrowth, however myogenesis ends and the ribs are still severely 
truncated (Figure 4-2 B red arrow).   In Myf-5loxP/loxP;MyoDiCre/Neo embryos, 
primary myogenesis is completely dependent on Mrf4.  In these embryos, rib 
outgrowth is the most advanced.  These embryos still die at birth and have very 
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little organized muscle.  However, the continual presence of muscle allows for rib 
outgrowth (Figure 4-2 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
Figure 4-1 
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Figure 4-1. Lack of Muscle in limb of E18.5 MyoDiCre/+;R26DTA embryos 
 
10 μm cryostat sections of wild type (D-F) and MyoDiCre/+;R26DTA limbs at E18.5.    
Myosin Heavy Chain antibody detection (B and E) show the absence of any 
myogenic cells in  MyoDiCre/+;R26DTA embryos.  Dapi is used to visualize nuclei (A 
and D) while (C and F) show phase images.  The forearm bones are seen as an 
absence of staining in B and in the phase images (C and F).  Scale bar 
represents 30 μm. 
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Figure 4-2. Rib Abnormality Phenotype in E18.5 Embryos with different 
MRF mutations 
 
Comparison of rib development in embryos with various myogenic mutations. 
There is no MyoD, Myf-5, or Mrf4 expression in (A) and rib development does not 
produce more than nubs (red arrow in A).  Rib development progresses more in 
B (red arrows) when early myotome formation is dependent on Myf-5 and Mrf4 
until the onset of MyoD expression causing cell death.  In Myf-
5loxP/loxP;MyoDiCre/Neo embryos (C) the only factor driving myogenesis is Mrf4 and 
produces the most 'normal' rib phenotype in comparison to the other genotypes. 
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4.5 Discussion: 
 
   Given the preliminary status of these experiments, it is difficult to draw 
many concrete conclusions.  However, given the striking phenotype when the 
MyoD expressing lineage is ablated,   it can be assumed that every cell in the 
myogenic lineage activates the MyoD locus during embryonic development.  This 
follows closely on the heels of the finding that all satellite cells activate the MyoD 
locus during embryogenesis (Kanisicak et al., 2009).  As an endpoint assay, it is 
striking to find no differentiated muscle at E18.5 in MyoDiCre/+;R26DTA embryos.  A 
detailed timeline of DTA dependent cell death needs to be performed in order to 
fully characterize this phenomenon. 
 When analyzing the MyoDiCre/+;R26DTA E18.5 embryos, the rib phenotype 
was impossible to miss.  The lack of skeletal muscle and limb phenotype was 
identical to the MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ phenotype described in chapter 
2, yet rib growth was much more pronounced, although still extremely poor in 
respect to wild type embryos.  The different rib phenotypes in the three 
genotypes analyzed, where myogenesis is disrupted at various time points, 
supports the hypothesis that rib growth is dependent on the myotome.  
MyoDiCre/Neo;Myf-5Neo/Neo  embryos have silenced Mrf4 expression, lack myoblast 
and myotome formation, and have the most severe rib truncation phenotype as 
myogenesis never begins (Kablar et al., 2003; Rudnicki et al., 1993).  In 
MyoDiCre/+;R26DTA  embryos, early myotome formation occurs, under the control 
of Myf-5 and Mrf4, until MyoD is activated at approximately E10, after which, all 
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muscle and myoblasts die and rib outgrowth stops.  This window of myogenesis 
appears to allow for more rib development.  In the third genotype examined, Myf-
5loxP/loxP;MyoDiCre/Neo  embryos have only Mrf4 to drive early myogenesis, which is 
not enough to form viable newborn mice (Kassar-Duchossoy et al., 2004). 
However, myogenesis occurs during embryogenesis and ribs develop much 
more than any other genotype analyzed here.  A more detailed analysis of these 
animals during development will show exactly when myogenesis fails and 
confirm signaling disruption between the sclerotome and myotome, and the 
resulting axial skeleton defects linked to those genotypes.            
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Chapter 5:  Conclusions and Future Directions 
 
5.1 Conclusions 
 
 All chapters of this thesis focus primarily on one member of the MRF gene 
family, MyoD.  In an attempt to refine the roles of the known cis-regulators of 
MyoD transcription, the CE and DRR, we have shown these DNA elements are 
not necessary to direct MyoD mRNA expression in a predominantly faithful 
manner compared to wild type embryos.  In embryos lacking the CE and DRR, 
aside from an approximately one day delay in initiation of MyoD expression in the 
limb buds and branchial arches, and a shorter delay in activation in the early 
myotome, MyoD expression occurs normally during development.  Knowing that 
the vast majority of transcriptional regulation does not lie in the CE and DRR, or 
the 15kb in between them, begins a new search for vital regulatory regions of this 
important gene.   
 These current experimental outcomes are the epitome of necessity vs. 
sufficiency.  The CE (258bp) and DRR (720bp) are sufficient to activate and 
maintain reporter gene transcription in a pattern nearly identical to MyoD's  
expression profile (Chen et al., 2001; Goldhamer et al., 1995; Kablar et al., 
1999).   When these elements are deleted, we find they are not necessary for 
proper regulation of the MyoD locus.  We have shown that the recently published 
reports focused on MyoD regulation via transcription factor binding to the CE are 
incomplete as this element is quite disposable for proper regulation (Andrews et 
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al., 2010; Havis et al., 2012; L'Honore et al., 2010; Yamamoto et al., 2007; Zhang 
et al., 2011).   It should be noted that these studies looked much more deeply 
into MyoD mRNA levels in their tissue or environment of interest than we did.  
Our analysis ended at E12.5, when the global MyoD mRNA profile appeared 
equivalent to wild type embryos.  Both of our new lines, MyoDΔCEDRR  and 
MyoDΔCE15DRR, are viable and healthy, but they may exhibit unknown postnatal 
transcriptional phenotypes.  The response these animals have to injury and 
regeneration may also be affected, and should be investigated in the future.    
Also, our genomic deletions have not led to improper, ectopic expression of 
MyoD, leaving no known areas that are capable of repressing MyoD 
transcription.  The state of chromatin surrounding the MyoD locus may control 
repression, as MyoD was discovered after demethylating fibroblasts, that in turn 
activate the MyoD locus and form muscle (Taylor and Jones, 1979). 
 These findings ignite the search for new enhancer regions. The location of  
possible enhancers abound, but based on the current knowledge of the locus, 
one may be slightly upstream of the CE, where a portion of F3 fragment remains.  
The F3 fragment has been shown to drive faithful reporter gene expression, and 
part of this fragment contains the CE (Goldhamer et al., 1995; Goldhamer et al., 
1992)).  Another possible regulatory target are the introns of MyoD.  This 
hypothesis is based on intronic enhancers in Myf-5 , sequence conservation 
across species, putative binging sites for transcriptional activators, and 
preliminary data from Dr. Yamamoto, whose work showed that replacement of 
the open reading frame of MyoD with the GFP gene results in an unexpected 
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absence of GFP in the myogenic lineage.  Whether this result is an artifact of the 
targeting design, or disruption of a new regulatory mechanism, should be 
pursued.  Intron 1 of MyoD appears to be involved in regulation also based on 
H3K4 tri-methylation levels.  A transgenic mouse embryo with intron one driving 
a reporter gene’s expression can be performed to address that possibility. 
 Replacement of the MyoD gene with the MyoD cDNA in mouse embryos 
will determine if introns are regulating MyoD expression.  To begin an unbiased 
search for enhancers, large scale BAC transgenes can be employed.  The BACs 
should contain the genomic DNA surrounding the MyoD gene and contain a 
reporter gene, with its own minimal promoter.  Large portions of the BAC can 
then be removed, followed by integration into the genome of murine ESCs to 
develop embryos and assayed for aberrant reporter gene expression.  Ultimately, 
the large deletions can be refined to discrete elements.  Chromatin 
Immunoprecipitation can also be used to identify trans-acting regulators, which 
are largely unknown, but several have been implicated in the introns of MyoD.  
Many recent studies have show transcription factors of interest binding the CE, 
but we now know that this interaction is not necessary for embryonic MyoD 
expression, and other regions should be investigated. 
 Linage tracing experiments presented in this thesis show strong support 
for MyoD being a determination factor in the trunk.  Observation of cells that 
normally would have contributed to skeletal muscle instead forming brown fat, 
cartilage and bone in the absence of MyoD shows these cells are not determined 
before MyoD expression.  The interpretation is complicated due to the absence 
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of the Myf-5 gene.  In embryos lacking only MyoD, all recombined cells contribute 
to the developing skeletal muscle.  Based on the preliminary data in Chapter4 
and Myf-5 lineage ablation studies (Gensch et al., 2008; Haldar et al., 2008), 
some portion of the recombined cells presumably express only MyoD and not 
Myf-5.  These cells may have fused to Myf-5 dependent muscle.  
 The difference in phenotype of progenitors in the limb versus the trunk 
should also be investigated.  Trunk progenitors can assume various fates, yet 
limb progenitors remain physically distinct from the surrounding fibroblastic 
mesenchyme, yet some express markers of the mesenchyme.  FACS isolation of 
recombined cells that arrive in the limb at different time points can be used for 
heterotopic transplantation to further assess the determination status of these 
cells.  Due to the long range migration, and lack of MRF expression before 
reaching the limb field, these cells may be strongly specified to the myogenic 
lineage while in the somite.  The contribution of labeled cells to bone in the trunk 
may be due to both lineages arising from paraxial mesoderm.  In the limb, bone 
progenitors come from the lateral plate mesoderm, and may be somehow 
refractory to contribution from somitically derived cells.    
 Also, if the genotype were changed such that the Myf-5loxP allele replaces 
the Myf-5Neo allele, information regarding Mrf4 dependent myogenesis could be 
uncovered.  In this scheme, Mrf4 expression is not compromised and 
myogenesis occurs, but not to the extent of myogenic rescue (Kassar-Duchossoy 
et al., 2004).   Looking for a fate change of the recombined cells in an embryo 
with some myogenesis would be informative as to the overlap between Mrf4 and 
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MyoD expression.  I would like to see if the recombined cells all contribute to the 
muscle, or if some still escape and become fat or cartilage.  The limb field is of 
particular interest, as minimal reports are available on the limb phenotype in 
MyoD/Myf-5 double mutants when the Mrf4 locus is unperturbed.   
 The MyoDiCre;R26DTA results add support to the new theory that all 
myogenic progenitors express MyoD during development.  Previous reports 
imply that there is a Myf-5 dependent lineage and a Myf-5 independent lineage.  
Now that all myoblasts and satellite cells (Kanisicak et al., 2009) express MyoD 
prenatally, it is even more interesting that MyoD null animals are viable and have 
reasonably normal muscle.  Some uncertainty exists when comparing Myf-5Cre 
studies to the current MyoDiCre studies.  The Myf-5Cre allele may be ectopically 
expressed.  Given the sensitivity of the Myf-5 locus to targeting, cells that should 
activate the allele may not, while other may activate it when inappropriate.   We 
have internally tested the MyoDiCre allele for specificity, and it appears to faithfully 
mimic MyoD mRNA expression. 
 The observation that the longer the myotome exists, the more complete rib 
development occurs requires extensive experimental refinement.  A 
developmental time courses during embryogenesis is needed to analyze exactly 
when myotome growth, and the resulting intercostal muscles,  starts and stops in 
the various genotypes used in these preliminary studies.  Our endpoint assay 
only shows a correlation, and is light on cause and effect.  Others have reported 
that PDGFR alpha and FGF signaling between the myotome and sclerotome is 
disrupted when the myotome is absent and this is the cause of the rib phenotype 
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(Tallquist et al., 2000).   Detection of these growth factors should be performed 
during development in the three genotypes analyzed here.  Also of interest is a 
study that shows terminal rib malformations in embryos lacking the two 
differentiation factors, Mrf4 and a reduced function version of Myogenin (Vivian et 
al., 2000).  This supports the hypothesis that myotome formation and  the 
maintenance of muscle is needed throughout rib development.  
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